BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol. 2012;8:643-657. [PMID: 23026949 DOI: 10.1038/nrneph.2012.214] [Cited by in Crossref: 349] [Cited by in F6Publishing: 291] [Article Influence: 34.9] [Reference Citation Analysis]
Number Citing Articles
1 Magro CM, Momtahen S, Mulvey JJ, Yassin AH, Kaplan RB, Laurence JC. Role of the skin biopsy in the diagnosis of atypical hemolytic uremic syndrome. Am J Dermatopathol 2015;37:349-56; quiz 357-9. [PMID: 25893747 DOI: 10.1097/DAD.0000000000000234] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
2 Graves RC, Fine RN. Kidney retransplantation in children following rejection and recurrent disease. Pediatr Nephrol 2016;31:2235-47. [DOI: 10.1007/s00467-016-3346-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
3 Johnson SA, Wong EK, Taylor CM. Making sense of the spectrum of glomerular disease associated with complement dysregulation. Pediatr Nephrol 2014;29:1883-94. [PMID: 23852337 DOI: 10.1007/s00467-013-2559-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
4 Mallett A, Patel C, Salisbury A, Wang Z, Healy H, Hoy W. The prevalence and epidemiology of genetic renal disease amongst adults with chronic kidney disease in Australia. Orphanet J Rare Dis 2014;9:98. [PMID: 24980890 DOI: 10.1186/1750-1172-9-98] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
5 Zuber J, Frimat M, Caillard S, Kamar N, Gatault P, Petitprez F, Couzi L, Jourde-Chiche N, Chatelet V, Gaisne R, Bertrand D, Bamoulid J, Louis M, Sberro Soussan R, Navarro D, Westeel PF, Frimat L, Colosio C, Thierry A, Rivalan J, Albano L, Arzouk N, Cornec-Le Gall E, Claisse G, Elias M, El Karoui K, Chauvet S, Coindre JP, Rerolle JP, Tricot L, Sayegh J, Garrouste C, Charasse C, Delmas Y, Massy Z, Hourmant M, Servais A, Loirat C, Fakhouri F, Pouteil-Noble C, Peraldi MN, Legendre C, Rondeau E, Le Quintrec M, Frémeaux-Bacchi V. Use of Highly Individualized Complement Blockade Has Revolutionized Clinical Outcomes after Kidney Transplantation and Renal Epidemiology of Atypical Hemolytic Uremic Syndrome. J Am Soc Nephrol 2019;30:2449-63. [PMID: 31575699 DOI: 10.1681/ASN.2019040331] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
6 Nieto-ríos JF, Serna-higuita LM, Calle-botero E, Ocampo-kohn C, Aristizabal-alzate A, Zuluaga-quintero M, Zuluaga-valencia G. Síndrome hemolítico urémico atípico en un paciente joven con compromiso renal, neurológico, ocular y cardiovascular. Nefrología 2016;36:82-5. [DOI: 10.1016/j.nefro.2015.07.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Schramm EC, Roumenina LT, Rybkine T, Chauvet S, Vieira-Martins P, Hue C, Maga T, Valoti E, Wilson V, Jokiranta S. Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome. Blood. 2015;125:2359-2369. [PMID: 25608561 DOI: 10.1182/blood-2014-10-609073] [Cited by in Crossref: 79] [Cited by in F6Publishing: 67] [Article Influence: 11.3] [Reference Citation Analysis]
8 Wada T, Nangaku M. Novel roles of complement in renal diseases and their therapeutic consequences. Kidney Int. 2013;84:441-450. [PMID: 23615508 DOI: 10.1038/ki.2013.134] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
9 Alasfar S, Alachkar N. Atypical hemolytic uremic syndrome post-kidney transplantation: two case reports and review of the literature. Front Med (Lausanne) 2014;1:52. [PMID: 25593925 DOI: 10.3389/fmed.2014.00052] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
10 Zelek WM, Menzies GE, Brancale A, Stockinger B, Morgan BP. Characterizing the original anti-C5 function-blocking antibody, BB5.1, for species specificity, mode of action and interactions with C5. Immunology 2020;161:103-13. [PMID: 32557571 DOI: 10.1111/imm.13228] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
11 Volokhina E, Wijnsma K, van der Molen R, Roeleveld N, van der Velden T, Goertz J, Sweep F, Brüggemann R, Wetzels J, van de Kar N, van den Heuvel L. Eculizumab Dosing Regimen in Atypical HUS: Possibilities for Individualized Treatment. Clin Pharmacol Ther 2017;102:671-8. [DOI: 10.1002/cpt.686] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
12 Hu X, Holers VM, Thurman JM, Schoeb TR, Ramos TN, Barnum SR. Therapeutic inhibition of the alternative complement pathway attenuates chronic EAE. Mol Immunol 2013;54:302-8. [PMID: 23337717 DOI: 10.1016/j.molimm.2012.12.018] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
13 Yung S, Yap DY, Chan TM. A review of advances in the understanding of lupus nephritis pathogenesis as a basis for emerging therapies. F1000Res 2020;9:F1000 Faculty Rev-905. [PMID: 32789005 DOI: 10.12688/f1000research.22438.1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
14 Konar M, Granoff DM. Eculizumab treatment and impaired opsonophagocytic killing of meningococci by whole blood from immunized adults. Blood 2017;130:891-9. [PMID: 28630122 DOI: 10.1182/blood-2017-05-781450] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 11.2] [Reference Citation Analysis]
15 Gulleroglu K, Fidan K, Hançer VS, Bayrakci U, Baskin E, Soylemezoglu O. Neurologic involvement in atypical hemolytic uremic syndrome and successful treatment with eculizumab. Pediatr Nephrol 2013;28:827-30. [PMID: 23389237 DOI: 10.1007/s00467-013-2416-9] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 4.4] [Reference Citation Analysis]
16 Fakhouri F, Frémeaux-bacchi V. Eculizumab for atypical haemolytic uraemic syndrome: what next? Nat Rev Nephrol 2013;9:495-6. [DOI: 10.1038/nrneph.2013.150] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
17 Greenwood GT. Case report of atypical hemolytic uremic syndrome with retinal arterial and venous occlusion treated with eculizumab. Int Med Case Rep J 2015;8:235-9. [PMID: 26508891 DOI: 10.2147/IMCRJ.S90640] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
18 Lemaire M, Frémeaux-Bacchi V, Schaefer F, Choi M, Tang WH, Le Quintrec M, Fakhouri F, Taque S, Nobili F, Martinez F. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet. 2013;45:531-536. [PMID: 23542698 DOI: 10.1038/ng.2590] [Cited by in Crossref: 317] [Cited by in F6Publishing: 261] [Article Influence: 35.2] [Reference Citation Analysis]
19 Kimman ML, Rotteveel AH, Wijsenbeek M, Mostard R, Tak NC, van Jaarsveld X, Storm M, Wijnsma KL, Gelens M, van de Kar NCAJ, Wetzels J, Dirksen CD. Development and Pretesting of a Questionnaire to Assess Patient Experiences and Satisfaction with Medications (PESaM Questionnaire). Patient 2017;10:629-42. [PMID: 28357591 DOI: 10.1007/s40271-017-0234-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
20 Ellington N, Wolf MTF, Kasten J, Rakheja D. Omental Arteriopathy in Primary Atypical Hemolytic Uremic Syndrome. Int J Surg Pathol 2017;25:515-7. [PMID: 28381151 DOI: 10.1177/1066896917699703] [Reference Citation Analysis]
21 Datta S, Singh S, Govindarajan R. Retrospective Analysis of Eculizumab in Patients with Acetylcholine Receptor Antibody-Negative Myasthenia Gravis: A Case Series. J Neuromuscul Dis 2020;7:269-77. [PMID: 32444555 DOI: 10.3233/JND-190464] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Bhakta V, Jenkins C, Ramirez-arcos S, Sheffield WP. Stability of relevant plasma protein activities in cryosupernatant plasma units during refrigerated storage for up to 5 days postthaw: Cryosupernatant Plasma Quality and Stability. Transfusion 2013. [DOI: 10.1111/trf.12254] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
23 Sarig G. ADAMTS-13 in the Diagnosis and Management of Thrombotic Microangiopathies. Rambam Maimonides Med J 2014;5:e0026. [PMID: 25386342 DOI: 10.5041/RMMJ.10160] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
24 Risitano AM. Current and Future Pharmacologic Complement Inhibitors. Hematology/Oncology Clinics of North America 2015;29:561-82. [DOI: 10.1016/j.hoc.2015.01.009] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
25 Okumi M, Tanabe K. Prevention and treatment of atypical haemolytic uremic syndrome after kidney transplantation. Nephrology (Carlton) 2016;21 Suppl 1:9-13. [PMID: 26988663 DOI: 10.1111/nep.12776] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
26 Pauly D, Nagel BM, Reinders J, Killian T, Wulf M, Ackermann S, Ehrenstein B, Zipfel PF, Skerka C, Weber BH. A novel antibody against human properdin inhibits the alternative complement system and specifically detects properdin from blood samples. PLoS One. 2014;9:e96371. [PMID: 24797388 DOI: 10.1371/journal.pone.0096371] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
27 Karpman D, Tati R. Complement activation in thrombotic microangiopathy. Hamostaseologie 2013;33:96-104. [PMID: 23411690 DOI: 10.5482/HAMO-12-12-0025] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
28 Bomback AS, Appel GB. Pathogenesis of the C3 glomerulopathies and reclassification of MPGN. Nat Rev Nephrol. 2012;8:634-642. [PMID: 23026947 DOI: 10.1038/nrneph.2012.213] [Cited by in Crossref: 97] [Cited by in F6Publishing: 81] [Article Influence: 9.7] [Reference Citation Analysis]
29 Cosio FG, Cattran DC. Recent advances in our understanding of recurrent primary glomerulonephritis after kidney transplantation. Kidney Int. 2017;91:304-314. [PMID: 27837947 DOI: 10.1016/j.kint.2016.08.030] [Cited by in Crossref: 76] [Cited by in F6Publishing: 63] [Article Influence: 12.7] [Reference Citation Analysis]
30 Mastellos DC, Ricklin D, Lambris JD. Clinical promise of next-generation complement therapeutics. Nat Rev Drug Discov 2019;18:707-29. [PMID: 31324874 DOI: 10.1038/s41573-019-0031-6] [Cited by in Crossref: 99] [Cited by in F6Publishing: 93] [Article Influence: 33.0] [Reference Citation Analysis]
31 Teoh CW, Riedl M, Licht C. The alternative pathway of complement and the thrombotic microangiopathies. Transfus Apher Sci. 2016;54:220-231. [PMID: 27160864 DOI: 10.1016/j.transci.2016.04.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
32 Afshar-Kharghan V. Atypical hemolytic uremic syndrome. Hematology Am Soc Hematol Educ Program 2016;2016:217-25. [PMID: 27913483 DOI: 10.1182/asheducation-2016.1.217] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
33 Greenbaum LA. Atypical Hemolytic Uremic Syndrome. Advances in Pediatrics 2014;61:335-56. [DOI: 10.1016/j.yapd.2014.04.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
34 Enjeti AK, de Malmanche T, Chapman K, Ziolkowski A. Genomic investigation of inherited thrombotic microangiopathy-aHUS and TTP. Int J Lab Hematol 2020;42 Suppl 1:33-40. [PMID: 32543063 DOI: 10.1111/ijlh.13201] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
35 Fakhouri F, Fila M, Provôt F, Delmas Y, Barbet C, Châtelet V, Rafat C, Cailliez M, Hogan J, Servais A, Karras A, Makdassi R, Louillet F, Coindre JP, Rondeau E, Loirat C, Frémeaux-Bacchi V. Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation. Clin J Am Soc Nephrol 2017;12:50-9. [PMID: 27799617 DOI: 10.2215/CJN.06440616] [Cited by in Crossref: 94] [Cited by in F6Publishing: 43] [Article Influence: 15.7] [Reference Citation Analysis]
36 Frémeaux-Bacchi V, Legendre CM. The emerging role of complement inhibitors in transplantation. Kidney Int 2015;88:967-73. [PMID: 26376132 DOI: 10.1038/ki.2015.253] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
37 Brachet G, Bourquard T, Gallay N, Reiter E, Gouilleux-gruart V, Poupon A, Watier H. Eculizumab epitope on complement C5: Progress towards a better understanding of the mechanism of action. Molecular Immunology 2016;77:126-31. [DOI: 10.1016/j.molimm.2016.07.016] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
38 Ueda Y, Miwa T, Ito D, Kim H, Sato S, Gullipalli D, Zhou L, Golla M, Song D, Dunaief JL, Palmer MB, Song WC. Differential contribution of C5aR and C5b-9 pathways to renal thrombic microangiopathy and macrovascular thrombosis in mice carrying an atypical hemolytic syndrome-related factor H mutation. Kidney Int 2019;96:67-79. [PMID: 30910380 DOI: 10.1016/j.kint.2019.01.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
39 Mukherjee AA, Kandhare AD, Bodhankar SL. Evaluation of health-related quality of life in hemolytic uraemic syndrome patients treated with eculizumab: a systematic evaluation on basis of EMPRO. Ren Fail 2018;40:107-18. [PMID: 29363392 DOI: 10.1080/0886022X.2018.1427110] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Fraga-Rodriguez GM, Brió-Sanagustin S, Turón-Viñas E, Dixon BP, Carreras-González E. Eculizumab in a child with atypical haemolytic uraemic syndrome and haemophagocytic lymphohistiocytosis triggered by cytomegalovirus infection. BMJ Case Rep 2017;2017:bcr-2016-219065. [PMID: 28446488 DOI: 10.1136/bcr-2016-219065] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
41 Han SS, Yu XJ, Wang SX, Zhou FD, Yu F, Zhao MH. A novel mutation in complement 2 accompanied by susceptibility variants in C3 glomerulonephritis: A case study. Nefrologia (Engl Ed) 2019;39:664-71. [PMID: 31014550 DOI: 10.1016/j.nefro.2019.01.008] [Reference Citation Analysis]
42 Cataland SR, Holers VM, Geyer S, Yang S, Wu HM. Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP. Blood 2014;123:3733-8. [PMID: 24695849 DOI: 10.1182/blood-2013-12-547067] [Cited by in Crossref: 106] [Cited by in F6Publishing: 92] [Article Influence: 13.3] [Reference Citation Analysis]
43 Chadban SJ, Ahn C, Axelrod DA, Foster BJ, Kasiske BL, Kher V, Kumar D, Oberbauer R, Pascual J, Pilmore HL, Rodrigue JR, Segev DL, Sheerin NS, Tinckam KJ, Wong G, Knoll GA. KDIGO Clinical Practice Guideline on the evaluation and management of candidates for kidney transplantation. Transplantation. 2020;104:S11-S103. [PMID: 32301874 DOI: 10.1097/tp.0000000000003136] [Cited by in Crossref: 60] [Cited by in F6Publishing: 22] [Article Influence: 60.0] [Reference Citation Analysis]
44 Williams LA, Marques MB; for the Education Committee of the Academy of Clinical Laboratory Physicians and Scientists. Pathology Consultation on the Diagnosis and Treatment of Thrombotic Microangiopathies (TMAs). Am J Clin Pathol 2016;145:158-65. [DOI: 10.1093/ajcp/aqv086] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
45 Michels MAHM, Volokhina EB, van de Kar NCAJ, van den Heuvel LPWJ. The role of properdin in complement-mediated renal diseases: a new player in complement-inhibiting therapy? Pediatr Nephrol 2019;34:1349-67. [PMID: 30141176 DOI: 10.1007/s00467-018-4042-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
46 Duineveld C, Verhave JC, Berger SP, van de Kar NC, Wetzels JF. Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome: A Case Series. American Journal of Kidney Diseases 2017;70:770-7. [DOI: 10.1053/j.ajkd.2017.06.024] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
47 Legendre C, Sberro-Soussan R, Zuber J, Frémeaux-Bacchi V. The role of complement inhibition in kidney transplantation. Br Med Bull 2017;124:5-17. [PMID: 29069327 DOI: 10.1093/bmb/ldx037] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
48 Tatapudi VS, Montgomery RA. Pharmacologic Complement Inhibition in Clinical Transplantation. Curr Transplant Rep 2017;4:91-100. [PMID: 29214126 DOI: 10.1007/s40472-017-0148-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
49 Paixão-Cavalcante D, Torreira E, Lindorfer MA, Rodriguez de Cordoba S, Morgan BP, Taylor RP, Llorca O, Harris CL. A humanized antibody that regulates the alternative pathway convertase: potential for therapy of renal disease associated with nephritic factors. J Immunol 2014;192:4844-51. [PMID: 24729617 DOI: 10.4049/jimmunol.1303131] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
50 Shen YM. Clinical evaluation of thrombotic microangiopathy: identification of patients with suspected atypical hemolytic uremic syndrome. Thromb J 2016;14:19. [PMID: 27766045 DOI: 10.1186/s12959-016-0114-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
51 Zikos TA, Sokolove J, Ahuja N, Berube C. Eculizumab Induces Sustained Remission in a Patient With Refractory Primary Catastrophic Antiphospholipid Syndrome. J Clin Rheumatol 2015;21:311-3. [PMID: 26267719 DOI: 10.1097/RHU.0000000000000290] [Cited by in Crossref: 50] [Cited by in F6Publishing: 19] [Article Influence: 8.3] [Reference Citation Analysis]
52 Cataland SR. Eculizumab Therapy. Biology of Blood and Marrow Transplantation 2014;20:438-9. [DOI: 10.1016/j.bbmt.2014.02.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
53 Caliskan Y, Lee B, Whelan AM, Abualrub F, Lentine KL, Jittirat A. Evaluation of Genetic Kidney Diseases in Living Donor Kidney Transplantation: Towards Precision Genomic Medicine in Donor Risk Assessment. Curr Transpl Rep. [DOI: 10.1007/s40472-021-00340-3] [Reference Citation Analysis]
54 Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingel R, Meyer E, Pham HP, Schneiderman J, Witt V, Wu Y, Zantek ND, Dunbar NM, Schwartz GEJ. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. J Clin Apher. 2019;34:171-354. [PMID: 31180581 DOI: 10.1002/jca.21705] [Cited by in Crossref: 314] [Cited by in F6Publishing: 277] [Article Influence: 104.7] [Reference Citation Analysis]
55 Cook HT. Complement and kidney disease: . Current Opinion in Nephrology and Hypertension 2013;22:295-301. [DOI: 10.1097/mnh.0b013e32835ff9cb] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
56 Sinibaldi S, Guzzo I, Piras R, Bresin E, Emma F, Dello Strologo L. Post-transplant recurrence of atypical hemolytic uremic syndrome in a patient with thrombomodulin mutation. Pediatr Transplant. 2013;17:E177-E181. [PMID: 24118826 DOI: 10.1111/petr.12151] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
57 Wang X, Van Lookeren Campagne M, Katschke KJ Jr, Gullipalli D, Miwa T, Ueda Y, Wang Y, Palmer M, Xing G, Song WC. Prevention of Fatal C3 Glomerulopathy by Recombinant Complement Receptor of the Ig Superfamily. J Am Soc Nephrol 2018;29:2053-9. [PMID: 29895552 DOI: 10.1681/ASN.2018030270] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
58 Claes KJ, Massart A, Collard L, Weekers L, Goffin E, Pochet JM, Dahan K, Morelle J, Adams B, Broeders N, Stordeur P, Abramowicz D, Bosmans JL, Van Hoeck K, Janssens P, Pipeleers L, Peeters P, Van Laecke S, Levtchenko E, Sprangers B, van den Heuvel L, Godefroid N, Van de Walle J. Belgian consensus statement on the diagnosis and management of patients with atypical hemolytic uremic syndrome. Acta Clin Belg. 2018;73:80-89. [PMID: 29058539 DOI: 10.1080/17843286.2017.1345185] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
59 Java A. Peri- and Post-operative Evaluation and Management of Atypical Hemolytic Uremic Syndrome (aHUS) in Kidney Transplantation. Adv Chronic Kidney Dis 2020;27:128-37. [PMID: 32553245 DOI: 10.1053/j.ackd.2019.11.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Harris CL, Pouw RB, Kavanagh D, Sun R, Ricklin D. Developments in anti-complement therapy; from disease to clinical trial. Mol Immunol 2018;102:89-119. [PMID: 30121124 DOI: 10.1016/j.molimm.2018.06.008] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 10.3] [Reference Citation Analysis]
61 Greenbaum LA, Fila M, Ardissino G, Al-Akash SI, Evans J, Henning P, Lieberman KV, Maringhini S, Pape L, Rees L, van de Kar NC, Vande Walle J, Ogawa M, Bedrosian CL, Licht C. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int 2016;89:701-11. [PMID: 26880462 DOI: 10.1016/j.kint.2015.11.026] [Cited by in Crossref: 141] [Cited by in F6Publishing: 119] [Article Influence: 23.5] [Reference Citation Analysis]
62 Loirat C, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura in children. Curr Opin Pediatr 2013;25:216-24. [PMID: 23422353 DOI: 10.1097/MOP.0b013e32835e7888] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
63 Wijnsma KL, Duineveld C, Wetzels JFM, van de Kar NCAJ. Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use. Pediatr Nephrol 2019;34:2261-77. [PMID: 30402748 DOI: 10.1007/s00467-018-4091-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
64 Liebau MC. An emerging molecular understanding and novel targeted treatment approaches in pediatric kidney diseases. Front Pediatr 2014;2:68. [PMID: 25050320 DOI: 10.3389/fped.2014.00068] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
65 Keating GM. Eculizumab: a review of its use in atypical haemolytic uraemic syndrome. Drugs. 2013;73:2053-2066. [PMID: 24249647 DOI: 10.1007/s40265-013-0147-7] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 4.5] [Reference Citation Analysis]
66 Riedl M, Hofer J, Giner T, Rosales A, Häffner K, Simonetti GD, Walden U, Maier T, Heininger D, Jeller V, Weiss G, van den Heuvel L, Zimmerhackl LB, Würzner R, Jungraithmayr TC. Novel biomarker and easy to perform ELISA for monitoring complement inhibition in patients with atypical hemolytic uremic syndrome treated with eculizumab. J Immunol Methods 2016;435:60-7. [PMID: 27238216 DOI: 10.1016/j.jim.2016.05.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
67 Loirat C, Mariani-Kurkdjian P, Fremeaux-Bacchi V. [Hemolytic uremic syndrome as of 2013]. Arch Pediatr 2013;20:827-30. [PMID: 23835098 DOI: 10.1016/j.arcped.2013.05.015] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
68 Durigutto P, Sblattero D, Biffi S, De Maso L, Garrovo C, Baj G, Colombo F, Fischetti F, Di Naro AF, Tedesco F, Macor P. Targeted Delivery of Neutralizing Anti-C5 Antibody to Renal Endothelium Prevents Complement-Dependent Tissue Damage. Front Immunol 2017;8:1093. [PMID: 28932227 DOI: 10.3389/fimmu.2017.01093] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
69 Ono M, Ohashi N, Namikawa A, Katahashi N, Ishigaki S, Tsuji N, Isobe S, Iwakura T, Sakao Y, Tsuji T, Kato A, Fujigaki Y, Shimizu A, Yasuda H. A Rare Case of Lupus Nephritis Presenting as Thrombotic Microangiopathy with Diffuse Pseudotubulization Possibly Caused by Atypical Hemolytic Uremic Syndrome. Intern Med 2018;57:1617-23. [PMID: 29434134 DOI: 10.2169/internalmedicine.0228-17] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
70 Timmermans SAMEG, Abdul-Hamid MA, Potjewijd J, Theunissen ROMFIH, Damoiseaux JGMC, Reutelingsperger CP, van Paassen P; Limburg Renal Registry. C5b9 Formation on Endothelial Cells Reflects Complement Defects among Patients with Renal Thrombotic Microangiopathy and Severe Hypertension. J Am Soc Nephrol 2018;29:2234-43. [PMID: 29858281 DOI: 10.1681/ASN.2018020184] [Cited by in Crossref: 35] [Cited by in F6Publishing: 18] [Article Influence: 8.8] [Reference Citation Analysis]
71 de Lorenzo A, Tallón S, Hernández-sevillano B, de Arriba G. C3 glomerulopathy: A new complement-based entity. Revista Clínica Española (English Edition) 2014;214:266-74. [DOI: 10.1016/j.rceng.2014.01.009] [Reference Citation Analysis]
72 Hisano M, Ashida A, Nakano E, Suehiro M, Yoshida Y, Matsumoto M, Miyata T, Fujimura Y, Hattori M. Autoimmune-type atypical hemolytic uremic syndrome treated with eculizumab as first-line therapy: Eculizumab for aHUS. Pediatr Int 2015;57:313-7. [DOI: 10.1111/ped.12469] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
73 Vitkauskaitė M, Vinikovas A, Miglinas M, Rimševičius L, Čerkauskaitė A, Mačionienė E, Ašakienė E. Complement inhibitor eculizumab in thrombotic microangiopathy: Single‐center case series. Clinical Case Reports 2022;10. [DOI: 10.1002/ccr3.5573] [Reference Citation Analysis]
74 Marinozzi MC, Vergoz L, Rybkine T, Ngo S, Bettoni S, Pashov A, Cayla M, Tabarin F, Jablonski M, Hue C. Complement factor B mutations in atypical hemolytic uremic syndrome-disease-relevant or benign? J Am Soc Nephrol. 2014;25:2053-2065. [PMID: 24652797 DOI: 10.1681/asn.2013070796] [Cited by in Crossref: 68] [Cited by in F6Publishing: 39] [Article Influence: 8.5] [Reference Citation Analysis]
75 Portuguese AJ, Gleber C, Passero FC, Lipe B. A review of thrombotic microangiopathies in multiple myeloma. Leukemia Research 2019;85:106195. [DOI: 10.1016/j.leukres.2019.106195] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
76 Krishnappa V, Gupta M, Elrifai M, Moftakhar B, Ensley MJ, Vachharajani TJ, Sethi SK, Raina R. Atypical Hemolytic Uremic Syndrome: A Meta-Analysis of Case Reports Confirms the Prevalence of Genetic Mutations and the Shift of Treatment Regimens: Meta-Analysis of Atypical HUS Case Reports. Therapeutic Apheresis and Dialysis 2018;22:178-88. [DOI: 10.1111/1744-9987.12641] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
77 Rosove MH. Thrombotic microangiopathies. Seminars in Arthritis and Rheumatism 2014;43:797-805. [DOI: 10.1016/j.semarthrit.2013.11.004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
78 Williams AL, Gullipalli D, Ueda Y, Sato S, Zhou L, Miwa T, Tung KS, Song WC. C5 inhibition prevents renal failure in a mouse model of lethal C3 glomerulopathy. Kidney Int 2017;91:1386-97. [PMID: 28139294 DOI: 10.1016/j.kint.2016.11.018] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
79 Adamski J. Thrombotic microangiopathy and indications for therapeutic plasma exchange. Hematology 2014;2014:444-9. [DOI: 10.1182/asheducation-2014.1.444] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
80 Weber B, Chan D, Hammer S. Eculizumab Use in a Temporarily Dialysis-Dependent Patient With Shiga Toxin-Producing Escherichia Coli Hemolytic Uremic Syndrome With Neurological Complications. J Pediatr Pharmacol Ther 2022;27:90-5. [PMID: 35002565 DOI: 10.5863/1551-6776-27.1.90] [Reference Citation Analysis]
81 Rees L. Atypical HUS: time to take stock of current guidelines and outcome measures? Pediatr Nephrol 2013;28:675-7. [PMID: 23389238 DOI: 10.1007/s00467-013-2423-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
82 Cristinziano L, Modestino L, Antonelli A, Marone G, Simon HU, Varricchi G, Galdiero MR. Neutrophil extracellular traps in cancer. Semin Cancer Biol 2021:S1044-579X(21)00206-6. [PMID: 34280576 DOI: 10.1016/j.semcancer.2021.07.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
83 Ekdahl KN, Teramura Y, Hamad OA, Asif S, Duehrkop C, Fromell K, Gustafson E, Hong J, Kozarcanin H, Magnusson PU, Huber-Lang M, Garred P, Nilsson B. Dangerous liaisons: complement, coagulation, and kallikrein/kinin cross-talk act as a linchpin in the events leading to thromboinflammation. Immunol Rev 2016;274:245-69. [PMID: 27782319 DOI: 10.1111/imr.12471] [Cited by in Crossref: 71] [Cited by in F6Publishing: 71] [Article Influence: 14.2] [Reference Citation Analysis]
84 Wortmann SB, Espeel M, Almeida L, Reimer A, Bosboom D, Roels F, de Brouwer AP, Wevers RA. Inborn errors of metabolism in the biosynthesis and remodelling of phospholipids. J Inherit Metab Dis 2015;38:99-110. [DOI: 10.1007/s10545-014-9759-7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 3.5] [Reference Citation Analysis]
85 Nguyen TC. Thrombocytopenia-Associated Multiple Organ Failure. Crit Care Clin 2020;36:379-90. [PMID: 32172819 DOI: 10.1016/j.ccc.2019.12.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
86 Román-Ortiz E, Mendizabal Oteiza S, Pinto S, López-Trascasa M, Sánchez-Corral P, Rodríguez de Cordoba S. Eculizumab long-term therapy for pediatric renal transplant in aHUS with CFH/CFHR1 hybrid gene. Pediatr Nephrol. 2014;29:149-153. [PMID: 23982707 DOI: 10.1007/s00467-013-2591-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
87 Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT. Complement System Part I - Molecular Mechanisms of Activation and Regulation. Front Immunol. 2015;6:262. [PMID: 26082779 DOI: 10.3389/fimmu.2015.00262] [Cited by in Crossref: 521] [Cited by in F6Publishing: 553] [Article Influence: 74.4] [Reference Citation Analysis]
88 Cofiell R, Kukreja A, Bedard K, Yan Y, Mickle AP, Ogawa M, Bedrosian CL, Faas SJ. Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. Blood 2015;125:3253-62. [PMID: 25833956 DOI: 10.1182/blood-2014-09-600411] [Cited by in Crossref: 109] [Cited by in F6Publishing: 96] [Article Influence: 15.6] [Reference Citation Analysis]
89 Licht C, Greenbaum LA, Muus P, Babu S, Bedrosian CL, Cohen DJ, Delmas Y, Douglas K, Furman RR, Gaber OA, Goodship T, Herthelius M, Hourmant M, Legendre CM, Remuzzi G, Sheerin N, Trivelli A, Loirat C. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int. 2015;87:1061-1073. [PMID: 25651368 DOI: 10.1038/ki.2014.423] [Cited by in Crossref: 234] [Cited by in F6Publishing: 194] [Article Influence: 33.4] [Reference Citation Analysis]
90 Biglarnia AR, Huber-Lang M, Mohlin C, Ekdahl KN, Nilsson B. The multifaceted role of complement in kidney transplantation. Nat Rev Nephrol 2018;14:767-81. [PMID: 30367174 DOI: 10.1038/s41581-018-0071-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
91 Hu H, Nagra A, Haq MR, Gilbert RD. Eculizumab in atypical haemolytic uraemic syndrome with severe cardiac and neurological involvement. Pediatr Nephrol 2014;29:1103-6. [DOI: 10.1007/s00467-013-2709-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
92 Kavanagh D, Raman S, Sheerin NS. Management of hemolytic uremic syndrome. F1000Prime Rep 2014;6:119. [PMID: 25580273 DOI: 10.12703/P6-119] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
93 Brocklebank V, Wood KM, Kavanagh D. Thrombotic Microangiopathy and the Kidney. Clin J Am Soc Nephrol. 2018;13:300-317. [PMID: 29042465 DOI: 10.2215/cjn.00620117] [Cited by in Crossref: 103] [Cited by in F6Publishing: 57] [Article Influence: 20.6] [Reference Citation Analysis]
94 Mallett A, Hughes P, Szer J, Tuckfield A, Van Eps C, Cambell SB, Hawley C, Burke J, Kausman J, Hewitt I, Parnham A, Ford S, Isbel N. Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort: Eculizumab treatment of aHUS in Australia. Intern Med J 2015;45:1054-65. [DOI: 10.1111/imj.12864] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
95 Bruneau S, Néel M, Roumenina LT, Frimat M, Laurent L, Frémeaux-Bacchi V, Fakhouri F. Loss of DGKε induces endothelial cell activation and death independently of complement activation. Blood 2015;125:1038-46. [PMID: 25498910 DOI: 10.1182/blood-2014-06-579953] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 7.4] [Reference Citation Analysis]
96 Bomback AS. Anti-complement therapy for glomerular diseases. Adv Chronic Kidney Dis. 2014;21:152-158. [PMID: 24602464 DOI: 10.1053/j.ackd.2013.12.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
97 Schäfer N, Grosche A, Reinders J, Hauck SM, Pouw RB, Kuijpers TW, Wouters D, Ehrenstein B, Enzmann V, Zipfel PF, Skerka C, Pauly D. Complement Regulator FHR-3 Is Elevated either Locally or Systemically in a Selection of Autoimmune Diseases. Front Immunol 2016;7:542. [PMID: 27965669 DOI: 10.3389/fimmu.2016.00542] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
98 Codina S, Manonelles A, Tormo M, Sola A, Cruzado JM. Chronic Kidney Allograft Disease: New Concepts and Opportunities. Front Med (Lausanne) 2021;8:660334. [PMID: 34336878 DOI: 10.3389/fmed.2021.660334] [Reference Citation Analysis]
99 Yüksel S, Evrengül H, Özçakar ZB, Becerir T, Yalçın N, Korkmaz E, Ozaltin F. First-Line, Early and Long-Term Eculizumab Therapy in Atypical Hemolytic Uremic Syndrome: A Case Series in Pediatric Patients. Pediatr Drugs 2016;18:413-20. [DOI: 10.1007/s40272-016-0194-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
100 Garcia BL, Skaff DA, Chatterjee A, Hanning A, Walker JK, Wyckoff GJ, Geisbrecht BV. Identification of C3b-Binding Small-Molecule Complement Inhibitors Using Cheminformatics. J Immunol 2017;198:3705-18. [PMID: 28298523 DOI: 10.4049/jimmunol.1601932] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
101 Ávila A, Gavela E, Sancho A. Thrombotic Microangiopathy After Kidney Transplantation: An Underdiagnosed and Potentially Reversible Entity. Front Med (Lausanne) 2021;8:642864. [PMID: 33898482 DOI: 10.3389/fmed.2021.642864] [Reference Citation Analysis]
102 Liszewski MK, Java A, Schramm EC, Atkinson JP. Complement Dysregulation and Disease: Insights from Contemporary Genetics. Annu Rev Pathol. 2017;12:25-52. [PMID: 27959629 DOI: 10.1146/annurev-pathol-012615-044145] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 6.8] [Reference Citation Analysis]
103 Volokhina EB, van de Kar NC, Bergseth G, van der Velden TJ, Westra D, Wetzels JF, van den Heuvel LP, Mollnes TE. Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome. Clinical Immunology 2015;160:237-43. [DOI: 10.1016/j.clim.2015.05.018] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 4.6] [Reference Citation Analysis]
104 Abbas F, El Kossi M, Jin JK, Sharma A, Halawa A. De novo glomerular diseases after renal transplantation: How is it different from recurrent glomerular diseases? World J Transplant 2017; 7(6): 285-300 [PMID: 29312858 DOI: 10.5500/wjt.v7.i6.285] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
105 Yeter HH, Sütiçen E, Korucu B, Helvaci Ö, Özbaş B, Gönül İ, Derici Ü, Arinsoy T, Güz G. Evaluation of Clinical, Laboratory and Treatment Modalities in C3 Glomerulopathy: Single Center Experience. Pril (Makedon Akad Nauk Umet Odd Med Nauki) 2019;40:15-23. [PMID: 31605593 DOI: 10.2478/prilozi-2019-0010] [Reference Citation Analysis]
106 Yamada Y. Nucleic Acid Drugs-Current Status, Issues, and Expectations for Exosomes. Cancers (Basel) 2021;13:5002. [PMID: 34638486 DOI: 10.3390/cancers13195002] [Reference Citation Analysis]
107 Sridharan M, Go RS, Willrich MAV. Atypical hemolytic uremic syndrome: Review of clinical presentation, diagnosis and management. J Immunol Methods 2018;461:15-22. [PMID: 30031798 DOI: 10.1016/j.jim.2018.07.006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
108 Matar D, Naqvi F, Racusen LC, Carter-Monroe N, Montgomery RA, Alachkar N. Atypical hemolytic uremic syndrome recurrence after kidney transplantation. Transplantation. 2014;98:1205-1212. [PMID: 24933457 DOI: 10.1097/tp.0000000000000200] [Cited by in Crossref: 41] [Cited by in F6Publishing: 19] [Article Influence: 5.9] [Reference Citation Analysis]
109 Wongsaroj P, Kahwaji J, Vo A, Jordan SC. Modern approaches to incompatible kidney transplantation. World J Nephrol 2015; 4(3): 354-362 [PMID: 26167458 DOI: 10.5527/wjn.v4.i3.354] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
110 Dedhia P, Govil A, Mogilishetty G, Alloway RR, Woodle ES, Abu Jawdeh BG. Eculizumab and Belatacept for De Novo Atypical Hemolytic Uremic Syndrome Associated With CFHR3-CFHR1 Deletion in a Kidney Transplant Recipient: A Case Report. Transplant Proc. 2017;49:188-192. [PMID: 28104134 DOI: 10.1016/j.transproceed.2016.11.008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 3.2] [Reference Citation Analysis]
111 Caliskan Y, Torun ES, Tiryaki TO, Oruc A, Ozluk Y, Akgul SU, Temurhan S, Oztop N, Kilicaslan I, Sever MS. Immunosuppressive Treatment in C3 Glomerulopathy: Is it Really Effective? Am J Nephrol 2017;46:96-107. [DOI: 10.1159/000479012] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
112 Rataj D, Werwitzke S, Haarmeijer B, Winkler M, Ramackers W, Petersen B, Niemann H, Wünsch A, Bähr A, Klymiuk N, Wolf E, Abicht J, Ayares D, Tiede A. Inhibition of complement component C5 prevents clotting in an ex vivo model of xenogeneic activation of coagulation. Xenotransplantation 2016;23:117-27. [DOI: 10.1111/xen.12218] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
113 Turley AJ, Gathmann B, Bangs C, Bradbury M, Seneviratne S, Gonzalez-Granado LI, Hackett S, Kutukculer N, Alachkar H, Hambleton S, Ritterbusch H, Kralickova P, Marodi L, Seidel MG, Dueckers G, Roesler J, Huissoon A, Baxendale H, Litzman J, Arkwright PD. Spectrum and management of complement immunodeficiencies (excluding hereditary angioedema) across Europe. J Clin Immunol 2015;35:199-205. [PMID: 25663093 DOI: 10.1007/s10875-015-0137-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
114 Merle NS, Noe R, Halbwachs-Mecarelli L, Fremeaux-Bacchi V, Roumenina LT. Complement System Part II: Role in Immunity. Front Immunol 2015;6:257. [PMID: 26074922 DOI: 10.3389/fimmu.2015.00257] [Cited by in Crossref: 353] [Cited by in F6Publishing: 385] [Article Influence: 50.4] [Reference Citation Analysis]
115 Chouaki Benmansour N, Carvelli J, Vivier É. [Involvement of the complement cascade in severe forms of COVID-19]. Med Sci (Paris) 2021;37:333-41. [PMID: 33835019 DOI: 10.1051/medsci/2021021] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
116 Fakhouri F, Delmas Y, Provot F, Barbet C, Karras A, Makdassi R, Courivaud C, Rifard K, Servais A, Allard C, Besson V, Cousin M, Châtelet V, Goujon J, Coindre J, Laurent G, Loirat C, Frémeaux-bacchi V. Insights From the Use in Clinical Practice of Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome Affecting the Native Kidneys: An Analysis of 19 Cases. American Journal of Kidney Diseases 2014;63:40-8. [DOI: 10.1053/j.ajkd.2013.07.011] [Cited by in Crossref: 58] [Cited by in F6Publishing: 54] [Article Influence: 7.3] [Reference Citation Analysis]
117 Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon SS, Kavanagh D, Haller H; 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. Kidney Int 2020;97:1287-96. [PMID: 32299680 DOI: 10.1016/j.kint.2020.01.035] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 15.5] [Reference Citation Analysis]
118 Johnson CK, Leca N. Eculizumab use in kidney transplantation. Curr Opin Organ Transplant 2015;20:643-51. [PMID: 26536427 DOI: 10.1097/MOT.0000000000000249] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
119 Bettoni S, Bresin E, Remuzzi G, Noris M, Donadelli R. Insights into the Effects of Complement Factor H on the Assembly and Decay of the Alternative Pathway C3 Proconvertase and C3 Convertase. J Biol Chem. 2016;291:8214-8230. [PMID: 26903516 DOI: 10.1074/jbc.m115.693119] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
120 Ryan M, Donato BMK, Irish W, Gasteyger C, L'Italien G, Laurence J. Economic Impact of Early-in-Hospital Diagnosis and Initiation of Eculizumab in Atypical Haemolytic Uraemic Syndrome. Pharmacoeconomics 2020;38:307-13. [PMID: 31828738 DOI: 10.1007/s40273-019-00862-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
121 Yamaguchi N, Misawa S, Sato Y, Nagashima K, Katayama K, Sekiguchi Y, Iwai Y, Amino H, Suichi T, Yokota T, Nishida Y, Kohara N, Hirata K, Nishiyama K, Yabe I, Kaida KI, Suzuki N, Nodera H, Tsuji S, Koike H, Kira JI, Hanaoka H, Kusunoki S, Kuwabara S; JET-GBS Group. A Prospective, Multicenter, Randomized Phase II Study to Evaluate the Efficacy and Safety of Eculizumab in Patients with Guillain-Barré Syndrome (GBS): Protocol of Japanese Eculizumab Trial for GBS (JET-GBS). JMIR Res Protoc 2016;5:e210. [PMID: 27821382 DOI: 10.2196/resprot.6610] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
122 Sánchez-Moreno A, De la Cerda F, Cabrera R, Fijo J, López-Trascasa M, Bedoya R, Rodríguez de Córdoba S, Ybot-González P. Eculizumab in dense-deposit disease after renal transplantation. Pediatr Nephrol 2014;29:2055-9. [PMID: 24908321 DOI: 10.1007/s00467-014-2839-y] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
123 Licht C, Ardissino G, Ariceta G, Cohen D, Cole JA, Gasteyger C, Greenbaum LA, Johnson S, Ogawa M, Schaefer F, Vande Walle J, Frémeaux-Bacchi V. The global aHUS registry: methodology and initial patient characteristics. BMC Nephrol 2015;16:207. [PMID: 26654630 DOI: 10.1186/s12882-015-0195-1] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 5.6] [Reference Citation Analysis]
124 Foster MH, Ord JR. Emerging immunotherapies for autoimmune kidney disease. Hum Vaccin Immunother 2019;15:876-90. [PMID: 30550361 DOI: 10.1080/21645515.2018.1555569] [Reference Citation Analysis]
125 Chauvet S, Roumenina LT, Bruneau S, Marinozzi MC, Rybkine T, Schramm EC, Java A, Atkinson JP, Aldigier JC, Bridoux F, Touchard G, Fremeaux-Bacchi V. A Familial C3GN Secondary to Defective C3 Regulation by Complement Receptor 1 and Complement Factor H. J Am Soc Nephrol 2016;27:1665-77. [PMID: 26471127 DOI: 10.1681/ASN.2015040348] [Cited by in Crossref: 27] [Cited by in F6Publishing: 14] [Article Influence: 3.9] [Reference Citation Analysis]
126 Hofer J, Giner T, Cortina G, Jungraithmayr T, Masalskiene J, Dobiliene D, Mitkiene R, Pundziene B, Rudaitis S. Successful living-related renal transplantation in a patient with factor H antibody-associated atypical hemolytic uremic syndrome. Pediatr Transplant 2015;19:E121-5. [PMID: 26037622 DOI: 10.1111/petr.12519] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
127 Vaterodt L, Holle J, Hüseman D, Müller D, Thumfart J. Short- and Long-Term Renal Outcome of Hemolytic-Uremic Syndrome in Childhood. Front Pediatr 2018;6:220. [PMID: 30131950 DOI: 10.3389/fped.2018.00220] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
128 Rabasco C, Cavero T, Román E, Rojas-Rivera J, Olea T, Espinosa M, Cabello V, Fernández-Juarez G, González F, Ávila A, Baltar JM, Díaz M, Alegre R, Elías S, Antón M, Frutos MA, Pobes A, Blasco M, Martín F, Bernis C, Macías M, Barroso S, de Lorenzo A, Ariceta G, López-Mendoza M, Rivas B, López-Revuelta K, Campistol JM, Mendizábal S, de Córdoba SR, Praga M; Spanish Group for the Study of Glomerular Diseases (GLOSEN). Effectiveness of mycophenolate mofetil in C3 glomerulonephritis. Kidney Int 2015;88:1153-60. [PMID: 26221755 DOI: 10.1038/ki.2015.227] [Cited by in Crossref: 79] [Cited by in F6Publishing: 61] [Article Influence: 11.3] [Reference Citation Analysis]
129 Zhang R, Zhou M, Qi J, Miao W, Zhang Z, Wu D, Han Y. Efficacy and Safety of Eculizumab in the Treatment of Transplant-Associated Thrombotic Microangiopathy: A Systematic Review and Meta-Analysis. Front Immunol 2020;11:564647. [PMID: 33552043 DOI: 10.3389/fimmu.2020.564647] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
130 Hoi AY, Ross L, Day J, Buchanan RRC. Immunotherapeutic strategies in antiphospholipid syndrome: Treatment beyond anticoagulation. Intern Med J 2017;47:250-6. [DOI: 10.1111/imj.13245] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
131 Scully M, Goodship T. How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome. Br J Haematol. 2014;164:759-766. [PMID: 24387053 DOI: 10.1111/bjh.12718] [Cited by in Crossref: 101] [Cited by in F6Publishing: 82] [Article Influence: 12.6] [Reference Citation Analysis]
132 Nguyen TC, Cruz MA, Carcillo JA. Thrombocytopenia-Associated Multiple Organ Failure and Acute Kidney Injury. Crit Care Clin 2015;31:661-74. [PMID: 26410136 DOI: 10.1016/j.ccc.2015.06.004] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 4.1] [Reference Citation Analysis]
133 Walle JV, Delmas Y, Ardissino G, Wang J, Kincaid JF, Haller H. Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment. J Nephrol 2017;30:127-34. [PMID: 26995002 DOI: 10.1007/s40620-016-0288-3] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 7.5] [Reference Citation Analysis]
134 López-Lera A, Corvillo F, Nozal P, Regueiro JR, Sánchez-Corral P, López-Trascasa M. Complement as a diagnostic tool in immunopathology. Semin Cell Dev Biol 2019;85:86-97. [PMID: 29292221 DOI: 10.1016/j.semcdb.2017.12.017] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
135 Oosterveld MJ, Garrelfs MR, Hoppe B, Florquin S, Roelofs JJ, van den Heuvel LP, Amann K, Davin JC, Bouts AH, Schriemer PJ. Eculizumab in Pediatric Dense Deposit Disease. Clin J Am Soc Nephrol. 2015;10:1773-1782. [PMID: 26316621 DOI: 10.2215/cjn.01360215] [Cited by in Crossref: 38] [Cited by in F6Publishing: 17] [Article Influence: 5.4] [Reference Citation Analysis]
136 Infante B, Rossini M, Leo S, Troise D, Netti GS, Ranieri E, Gesualdo L, Castellano G, Stallone G. Recurrent Glomerulonephritis after Renal Transplantation: The Clinical Problem. Int J Mol Sci 2020;21:E5954. [PMID: 32824988 DOI: 10.3390/ijms21175954] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
137 Mastellos DC, Ricklin D, Yancopoulou D, Risitano A, Lambris JD. Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape. Expert Rev Hematol 2014;7:583-98. [PMID: 25213458 DOI: 10.1586/17474086.2014.953926] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
138 Ricklin D, Reis ES, Lambris JD. Complement in disease: a defence system turning offensive. Nat Rev Nephrol. 2016;12:383-401. [PMID: 27211870 DOI: 10.1038/nrneph.2016.70] [Cited by in Crossref: 248] [Cited by in F6Publishing: 246] [Article Influence: 41.3] [Reference Citation Analysis]
139 McCullough JW, Renner B, Thurman JM. The role of the complement system in acute kidney injury. Semin Nephrol 2013;33:543-56. [PMID: 24161039 DOI: 10.1016/j.semnephrol.2013.08.005] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 6.3] [Reference Citation Analysis]
140 Abbas F, El Kossi M, Kim JJ, Shaheen IS, Sharma A, Halawa A. Complement-mediated renal diseases after kidney transplantation - current diagnostic and therapeutic options in de novo and recurrent diseases. World J Transplantation 2018; 8(6): 203-219 [PMID: 30370231 DOI: 10.5500/wjt.v8.i6.203] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
141 Mckenna GJ, Klintmalm GB. Induction and Maintenance of Immunosuppression. Transplantation of the Liver. Elsevier; 2015. pp. 1264-88. [DOI: 10.1016/b978-1-4557-0268-8.00091-9] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
142 Morgan BP, Harris CL. Complement, a target for therapy in inflammatory and degenerative diseases. Nat Rev Drug Discov 2015;14:857-77. [PMID: 26493766 DOI: 10.1038/nrd4657] [Cited by in Crossref: 227] [Cited by in F6Publishing: 210] [Article Influence: 32.4] [Reference Citation Analysis]
143 Jamme M, Raimbourg Q, Chauveau D, Seguin A, Presne C, Perez P, Gobert P, Wynckel A, Provôt F, Delmas Y, Mousson C, Servais A, Vrigneaud L, Veyradier A, Rondeau E, Coppo P; French Thrombotic Microangiopathies Reference Centre. Predictive features of chronic kidney disease in atypical haemolytic uremic syndrome. PLoS One 2017;12:e0177894. [PMID: 28542627 DOI: 10.1371/journal.pone.0177894] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
144 Szarvas N, Szilágyi Á, Tasic V, Nushi-Stavileci V, Sofijanova A, Gucev Z, Szabó M, Szabó A, Szeifert L, Reusz G, Rusai K, Arbeiter K, Müller T, Prohászka Z. First-line therapy in atypical hemolytic uremic syndrome: consideration on infants with a poor prognosis. Ital J Pediatr 2014;40:101. [PMID: 25496981 DOI: 10.1186/s13052-014-0101-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
145 Webb TN, Griffiths H, Miyashita Y, Bhatt R, Jaffe R, Moritz M, Hofer J, Swiatecka-Urban A. Atypical Hemolytic Uremic Syndrome and Chronic Ulcerative Colitis Treated with Eculizumab. Int J Med Pharm Case Reports 2015;4:105-12. [PMID: 27135055 DOI: 10.9734/IJMPCR/2015/18771] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
146 Kaplan BS, Ruebner RL, Copelovitch L. Eculizumab treatment of atypical hemolytic uremic syndrome. Expert Opinion on Orphan Drugs 2012. [DOI: 10.1080/21678707.2013.750579] [Reference Citation Analysis]
147 Gonzalez Suarez ML, Thongprayoon C, Mao MA, Leeaphorn N, Bathini T, Cheungpasitporn W. Outcomes of Kidney Transplant Patients with Atypical Hemolytic Uremic Syndrome Treated with Eculizumab: A Systematic Review and Meta-Analysis. J Clin Med 2019;8:E919. [PMID: 31252541 DOI: 10.3390/jcm8070919] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
148 Tiscia GL, Ostuni A, Cascavilla N, Cappucci F, Scalzulli P, Battista C, Abrescia A, Aucella F, Buquicchio C, Brigante M, D’andrea G, Di Paolo B, Giordano G, Infante B, Piano S, Ranieri P, Tullo L, Grandone E. Validation of PLASMIC score and follow-up data in a cohort of patients with suspected microangiopathies from Southern Italy. J Thromb Thrombolysis 2018;46:174-9. [DOI: 10.1007/s11239-018-1674-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
149 Aigner C, Böhmig GA, Eskandary F, Herkner H, Prohászka Z, Csuka D, Kain R, Gaggl M, Sunder-Plassmann R, Müller-Sacherer T, Oszwald A, Fischer G, Schmidt A, Sunder-Plassmann G. Preemptive plasma therapy prevents atypical hemolytic uremic syndrome relapse in kidney transplant recipients. Eur J Intern Med 2020;73:51-8. [PMID: 31791575 DOI: 10.1016/j.ejim.2019.11.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
150 Mikes B, Sinkovits G, Farkas P, Csuka D, Rázsó K, Réti M, Radványi G, Demeter J, Prohászka Z. Carboxiterminal pro-endothelin-1 as an endothelial cell biomarker in thrombotic thrombocytopenic purpura. Thromb Haemost 2016;115:1034-43. [PMID: 26763086 DOI: 10.1160/TH15-07-0564] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
151 Kuwabara S, Misawa S. Future treatment for Guillain-Barré syndrome. Clin Exp Neuroimmunol 2016;7:320-3. [DOI: 10.1111/cen3.12343] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
152 Togarsimalemath SK, Sethi SK, Duggal R, Le Quintrec M, Jha P, Daniel R, Gonnet F, Bansal S, Roumenina LT, Fremeaux-Bacchi V, Kher V, Dragon-Durey MA. A novel CFHR1-CFHR5 hybrid leads to a familial dominant C3 glomerulopathy. Kidney Int 2017;92:876-87. [PMID: 28729035 DOI: 10.1016/j.kint.2017.04.025] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 5.2] [Reference Citation Analysis]
153 Brunelli SM, Claxton A, Mehta S, Anum EA. Consequences of hemolytic uremic syndrome among hemodialysis patients. J Nephrol 2015;28:361-7. [PMID: 25491936 DOI: 10.1007/s40620-014-0149-x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
154 Scully M. Thrombocytopenia in hospitalized patients: approach to the patient with thrombotic microangiopathy. Hematology Am Soc Hematol Educ Program 2017;2017:651-9. [PMID: 29222317 DOI: 10.1182/asheducation-2017.1.651] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
155 Calvaruso L, Naticchia A, Ferraro PM, Vischini G, Costanzi S. Deterioration in Clinical Status Is Not Enough to Suspend Eculizumab: A Genetic Complement-Mediated Atypical Hemolytic Uremic Syndrome Case Report. Case Rep Nephrol 2019;2019:9264824. [PMID: 31360562 DOI: 10.1155/2019/9264824] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
156 Ankawi GA, Clark WF. Atypical haemolytic uremic syndrome (aHUS) and membranoproliferative glomerulonephritis (MPGN), different diseases or a spectrum of complement-mediated glomerular diseases? BMJ Case Rep 2017;2017:bcr-2017-220974. [PMID: 28798244 DOI: 10.1136/bcr-2017-220974] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
157 Rafiq A, Tariq H, Abbas N, Shenoy R. Atypical hemolytic-uremic syndrome: a case report and literature review. Am J Case Rep 2015;16:109-14. [PMID: 25708146 DOI: 10.12659/AJCR.892907] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
158 Green H, Harari E, Davidovits M, Blickstein D, Grossman A, Gafter U, Gafter-gvili A. Atypical HUS due to factor H antibodies in an adult patient successfully treated with eculizumab. Renal Failure 2014;36:1119-21. [DOI: 10.3109/0886022x.2014.917574] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
159 Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa L, Espinosa M, Grinyó JM, Macía M, Mendizábal S, Praga M, Román E, Torra R, Valdés F, Vilalta R, Rodríguez de Córdoba S. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia 2015;35:421-47. [PMID: 26456110 DOI: 10.1016/j.nefro.2015.07.005] [Cited by in Crossref: 88] [Cited by in F6Publishing: 63] [Article Influence: 12.6] [Reference Citation Analysis]
160 Willrich MA, Andreguetto BD, Sridharan M, Fervenza FC, Tostrud LJ, Ladwig PM, Rivard AM, Hetrick MD, Olson RN, Bryant SC, Snyder MR, Murray DL. The impact of eculizumab on routine complement assays. Journal of Immunological Methods 2018;460:63-71. [DOI: 10.1016/j.jim.2018.06.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
161 Ozkaya O, Nalcacioglu H, Tekcan D, Genc G, Meydan BC, Ozdemir BH, Baysal MK, Keceligil HT. Eculizumab therapy in a patient with dense-deposit disease associated with partial lipodystropy. Pediatr Nephrol 2014;29:1283-7. [PMID: 24464478 DOI: 10.1007/s00467-013-2748-5] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 3.9] [Reference Citation Analysis]
162 Anastaze Stelle K, Gonzalez E, Wilhelm-Bals A, Michelet PR, Korff CM, Parvex P. Successful treatment of neonatal atypical hemolytic uremic syndrome with C5 monoclonal antibody. Arch Pediatr 2016;23:283-6. [PMID: 26775886 DOI: 10.1016/j.arcped.2015.11.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
163 Picard C, Burtey S, Bornet C, Curti C, Montana M, Vanelle P. Pathophysiology and treatment of typical and atypical hemolytic uremic syndrome. Pathologie Biologie 2015;63:136-43. [DOI: 10.1016/j.patbio.2015.03.001] [Cited by in Crossref: 30] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
164 Holmdahl R, Nimmerjahn F, Ludwig RJ. Editorial: Autoantibodies. Front Immunol 2019;10:484. [PMID: 31001243 DOI: 10.3389/fimmu.2019.00484] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
165 Laudisi F, Spreafico R, Evrard M, Hughes TR, Mandriani B, Kandasamy M, Morgan BP, Sivasankar B, Mortellaro A. Cutting edge: the NLRP3 inflammasome links complement-mediated inflammation and IL-1β release. J Immunol 2013;191:1006-10. [PMID: 23817414 DOI: 10.4049/jimmunol.1300489] [Cited by in Crossref: 118] [Cited by in F6Publishing: 116] [Article Influence: 13.1] [Reference Citation Analysis]
166 Kim S, Park E, Min SI, Yi NJ, Ha J, Ha IS, Cheong HI, Kang HG. Kidney Transplantation in Patients with Atypical Hemolytic Uremic Syndrome due to Complement Factor H Deficiency: Impact of Liver Transplantation. J Korean Med Sci 2018;33:e4. [PMID: 29215813 DOI: 10.3346/jkms.2018.33.e4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
167 Holmberg C. Combined liver and kidney transplantation: Who and when? Pediatr Transplant 2015;19:810-2. [PMID: 26767486 DOI: 10.1111/petr.12632] [Reference Citation Analysis]
168 Roumenina LT, Zuber J, Frémeaux-Bacchi V. Physiological and therapeutic complement regulators in kidney transplantation. Curr Opin Organ Transplant 2013;18:421-9. [PMID: 23838647 DOI: 10.1097/MOT.0b013e32836370ce] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
169 Nilles KM, Levitsky J. Current and Evolving Indications for Simultaneous Liver Kidney Transplantation. Semin Liver Dis 2021;41:308-20. [PMID: 34130337 DOI: 10.1055/s-0041-1729969] [Reference Citation Analysis]
170 Broeders EN, Stordeur P, Rorive S, Dahan K. A 'silent', new polymorphism of factor H and apparent de novo atypical haemolytic uraemic syndrome after kidney transplantation. BMJ Case Rep 2014;2014:bcr2014207630. [PMID: 25538218 DOI: 10.1136/bcr-2014-207630] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
171 Verhave JC, Wetzels JF, van de Kar NC. Novel aspects of atypical haemolytic uraemic syndrome and the role of eculizumab. Nephrol Dial Transplant 2014;29 Suppl 4:iv131-41. [PMID: 25165180 DOI: 10.1093/ndt/gfu235] [Cited by in Crossref: 46] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
172 Favre GA, Touzot M, Fremeaux-bacchi V, Hyvernat H, Gueffet J, Rohrlich PS, Queyrel V, Esnault V, Fakhouri F. Malignancy and thrombotic microangiopathy or atypical haemolytic and uraemic syndrome? Br J Haematol 2014;166:802-5. [DOI: 10.1111/bjh.12907] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
173 Risitano AM, Marotta S. Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future. Semin Immunol 2016;28:223-40. [PMID: 27346521 DOI: 10.1016/j.smim.2016.05.001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
174 Dretler AW, Rouphael NG, Stephens DS. Progress toward the global control of Neisseria meningitidis: 21st century vaccines, current guidelines, and challenges for future vaccine development. Hum Vaccin Immunother 2018;14:1146-60. [PMID: 29543582 DOI: 10.1080/21645515.2018.1451810] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 7.8] [Reference Citation Analysis]
175 de Haan A, Eijgelsheim M, Vogt L, Knoers NVAM, de Borst MH. Diagnostic Yield of Next-Generation Sequencing in Patients With Chronic Kidney Disease of Unknown Etiology. Front Genet 2019;10:1264. [PMID: 31921302 DOI: 10.3389/fgene.2019.01264] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
176 de Andrade LGM, Contti MM, Nga HS, Bravin AM, Takase HM, Viero RM, da Silva TN, Chagas KN, Palma LMP. Long-term outcomes of the Atypical Hemolytic Uremic Syndrome after kidney transplantation treated with eculizumab as first choice. PLoS One 2017;12:e0188155. [PMID: 29136640 DOI: 10.1371/journal.pone.0188155] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
177 Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa L, Espinosa M, Grinyó JM, Macía M, Mendizábal S, Praga M, Román E, Torra R, Valdés F, Vilalta R, Rodríguez de Córdoba S. An update for atypical haemolytic uraemic syndrome: Diagnosis and treatment. A consensus document. Nefrología (English Edition) 2015;35:421-47. [DOI: 10.1016/j.nefroe.2015.11.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.1] [Reference Citation Analysis]
178 Charmetant X, Jolivot A, Fournier T, Puthet JC, Cassier P, Lemoine S, Juillard L. [Gemcitabine-induced thrombotic microangiopathy: Can we improve screening and treatment?]. Nephrol Ther 2017;13:251-4. [PMID: 28499586 DOI: 10.1016/j.nephro.2016.12.003] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
179 Cornec-Le Gall E, Delmas Y, De Parscau L, Doucet L, Ogier H, Benoist JF, Fremeaux-Bacchi V, Le Meur Y. Adult-onset eculizumab-resistant hemolytic uremic syndrome associated with cobalamin C deficiency. Am J Kidney Dis 2014;63:119-23. [PMID: 24210589 DOI: 10.1053/j.ajkd.2013.08.031] [Cited by in Crossref: 60] [Cited by in F6Publishing: 44] [Article Influence: 6.7] [Reference Citation Analysis]
180 Devuyst O, Knoers NV, Remuzzi G, Schaefer F; Board of the Working Group for Inherited Kidney Diseases of the European Renal Association and European Dialysis and Transplant Association. Rare inherited kidney diseases: challenges, opportunities, and perspectives. Lancet 2014;383:1844-59. [PMID: 24856029 DOI: 10.1016/S0140-6736(14)60659-0] [Cited by in Crossref: 123] [Cited by in F6Publishing: 63] [Article Influence: 15.4] [Reference Citation Analysis]
181 Salemi S, Markovic M, Martini G, D'Amelio R. The expanding role of therapeutic antibodies. Int Rev Immunol 2015;34:202-64. [PMID: 24471447 DOI: 10.3109/08830185.2013.863304] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
182 Noone D, Waters A, Pluthero FG, Geary DF, Kirschfink M, Zipfel PF, Licht C. Successful treatment of DEAP-HUS with eculizumab. Pediatr Nephrol 2014;29:841-51. [DOI: 10.1007/s00467-013-2654-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
183 Eskandary F, Wahrmann M, Mühlbacher J, Böhmig GA. Complement inhibition as potential new therapy for antibody-mediated rejection. Transpl Int 2016;29:392-402. [DOI: 10.1111/tri.12706] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 3.1] [Reference Citation Analysis]
184 Sanghera P, Ghanta M, Ozay F, Ariyamuthu VK, Tanriover B. Kidney Diseases Associated With Alternative Complement Pathway Dysregulation and Potential Treatment Options. Am J Med Sci. 2017;354:533-538. [PMID: 29208248 DOI: 10.1016/j.amjms.2017.03.024] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
185 Vellanki VS, Bargman JM. Aspergillus Niger peritonitis in a peritoneal dialysis patient treated with eculizumab. Renal Failure 2014;36:631-3. [DOI: 10.3109/0886022x.2014.882712] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
186 Wijnsma KL, Ter Heine R, Moes DJAR, Langemeijer S, Schols SEM, Volokhina EB, van den Heuvel LP, Wetzels JFM, van de Kar NCAJ, Brüggemann RJ. Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab. Clin Pharmacokinet 2019;58:859-74. [PMID: 30758736 DOI: 10.1007/s40262-019-00742-8] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 19.0] [Reference Citation Analysis]
187 Cataland SR, Wu HM. Atypical hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: Clinically differentiating the thrombotic microangiopathies. European Journal of Internal Medicine 2013;24:486-91. [DOI: 10.1016/j.ejim.2013.05.007] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 3.7] [Reference Citation Analysis]
188 Tatapudi VS, Montgomery RA. Therapeutic Modulation of the Complement System in Kidney Transplantation: Clinical Indications and Emerging Drug Leads. Front Immunol 2019;10:2306. [PMID: 31632397 DOI: 10.3389/fimmu.2019.02306] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
189 Yenerel MN. Atypical Hemolytic Uremic Syndrome: Differential Diagnosis from TTP/HUS and Management. Turk J Haematol 2014;31:216-25. [PMID: 25319590 DOI: 10.4274/tjh.2013.0374] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
190 Frémeaux-Bacchi V. [Pathophysiology of atypical hemolytic uremic syndrome. Ten years of progress, from laboratory to patient]. Biol Aujourdhui 2013;207:231-40. [PMID: 24594571 DOI: 10.1051/jbio/2013027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
191 Besbas N, Gulhan B, Gucer S, Korkmaz E, Ozaltin F. A novel CFHR5 mutation associated with C3 glomerulonephritis in a Turkish girl. J Nephrol. 2014;27:457-460. [PMID: 24536001 DOI: 10.1007/s40620-013-0008-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
192 Baskin E, Gulleroglu K, Kantar A, Bayrakci U, Ozkaya O. Success of eculizumab in the treatment of atypical hemolytic uremic syndrome. Pediatr Nephrol 2015;30:783-9. [DOI: 10.1007/s00467-014-3003-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
193 Afshar-Kharghan V. The role of the complement system in cancer. J Clin Invest 2017;127:780-9. [PMID: 28248200 DOI: 10.1172/JCI90962] [Cited by in Crossref: 163] [Cited by in F6Publishing: 115] [Article Influence: 32.6] [Reference Citation Analysis]
194 Benamu E, Montoya JG. Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis. Curr Opin Infect Dis 2016;29:319-29. [PMID: 27257797 DOI: 10.1097/QCO.0000000000000279] [Cited by in Crossref: 74] [Cited by in F6Publishing: 32] [Article Influence: 18.5] [Reference Citation Analysis]
195 Avasare RS, Canetta PA, Bomback AS, Marasa M, Caliskan Y, Ozluk Y, Li Y, Gharavi AG, Appel GB. Mycophenolate Mofetil in Combination with Steroids for Treatment of C3 Glomerulopathy: A Case Series. Clin J Am Soc Nephrol 2018;13:406-13. [PMID: 29326307 DOI: 10.2215/CJN.09080817] [Cited by in Crossref: 28] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
196 Beck BB, van Spronsen F, Diepstra A, Berger RM, Kömhoff M. Renal thrombotic microangiopathy in patients with cblC defect: review of an under-recognized entity. Pediatr Nephrol 2017;32:733-41. [PMID: 27289364 DOI: 10.1007/s00467-016-3399-0] [Cited by in Crossref: 45] [Cited by in F6Publishing: 32] [Article Influence: 7.5] [Reference Citation Analysis]
197 Thurman JM, Serkova NJ. Nanosized contrast agents to noninvasively detect kidney inflammation by magnetic resonance imaging. Adv Chronic Kidney Dis. 2013;20:488-499. [PMID: 24206601 DOI: 10.1053/j.ackd.2013.06.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
198 Rathbone J, Kaltenthaler E, Richards A, Tappenden P, Bessey A, Cantrell A. A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS). BMJ Open. 2013;3:e003573. [PMID: 24189082 DOI: 10.1136/bmjopen-2013-003573] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 6.6] [Reference Citation Analysis]
199 Wehling C, Amon O, Bommer M, Hoppe B, Kentouche K, Schalk G, Weimer R, Wiesener M, Hohenstein B, Tönshoff B, Büscher R, Fehrenbach H, Gök ÖN, Kirschfink M. Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders. Clin Exp Immunol 2017;187:304-15. [PMID: 27784126 DOI: 10.1111/cei.12890] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 7.2] [Reference Citation Analysis]
200 Sprangers B, Kuypers DR. Recurrence of glomerulonephritis after renal transplantation. Transplant Rev (Orlando). 2013;27:126-134. [PMID: 23954034 DOI: 10.1016/j.trre.2013.07.004] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 3.2] [Reference Citation Analysis]
201 Klämbt V, Gimpel C, Bald M, Gerken C, Billing H, Loos S, Hansen M, König J, Vinke T, Montoya C, Sperandio BL, Kirschstein M, Hennies I, Pohl M, Häffner K. Different approaches to long-term treatment of aHUS due to MCP mutations: a multicenter analysis. Pediatr Nephrol 2021;36:463-71. [PMID: 32715379 DOI: 10.1007/s00467-020-04714-0] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
202 Gavriilaki E, Anagnostopoulos A, Mastellos DC. Complement in Thrombotic Microangiopathies: Unraveling Ariadne's Thread Into the Labyrinth of Complement Therapeutics. Front Immunol 2019;10:337. [PMID: 30891033 DOI: 10.3389/fimmu.2019.00337] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 11.7] [Reference Citation Analysis]
203 Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre A, Coppo R, Emma F, Johnson S, Karpman D. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2016;31:15-39. [PMID: 25859752 DOI: 10.1007/s00467-015-3076-8] [Cited by in Crossref: 272] [Cited by in F6Publishing: 210] [Article Influence: 38.9] [Reference Citation Analysis]
204 Ahmed Ali EM, Abbakar NM, Abdel Raheem MB, Ellidir RA. Characteristics and outcome of hemolytic uremic syndrome in Sudanese children in a single Centre in Khartoum State. Sudan J Paediatr 2017;17:42-8. [PMID: 29545664 DOI: 10.24911/SJP.2017.2.5] [Reference Citation Analysis]
205 Demir E, Yazici H, Ozluk Y, Kilicaslan I, Turkmen A. Pregnant Woman with Atypical Hemolytic Uremic Syndrome Delivered a Healthy Newborn under Eculizumab Treatment. Case Rep Nephrol Dial 2016;6:143-8. [PMID: 28101502 DOI: 10.1159/000454946] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
206 Le Quintrec M, Lionet A, Kandel C, Bourdon F, Gnemmi V, Colombat M, Goujon JM, Frémeaux-Bacchi V, Fakhouri F. Eculizumab for treatment of rapidly progressive C3 glomerulopathy. Am J Kidney Dis. 2015;65:484-489. [PMID: 25530108 DOI: 10.1053/j.ajkd.2014.09.025] [Cited by in Crossref: 69] [Cited by in F6Publishing: 59] [Article Influence: 8.6] [Reference Citation Analysis]
207 Fakhouri F, Zuber J, Frémeaux-Bacchi V, Loirat C. Haemolytic uraemic syndrome. Lancet 2017;390:681-96. [PMID: 28242109 DOI: 10.1016/S0140-6736(17)30062-4] [Cited by in Crossref: 202] [Cited by in F6Publishing: 108] [Article Influence: 40.4] [Reference Citation Analysis]
208 Sheerin NS, Glover E. Haemolytic uremic syndrome: diagnosis and management. F1000Res 2019;8:F1000 Faculty Rev-1690. [PMID: 31598213 DOI: 10.12688/f1000research.19957.1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
209 Nga HS, Palma LMP, Ernandes Neto M, Fernandes-Charpiot IMM, Garcia VD, Kist R, Miranda SMC, Macedo de Souza PA, Pereira GM Jr, de Andrade LGM. Thrombotic microangiopathy after kidney transplantation: Analysis of the Brazilian Atypical Hemolytic Uremic Syndrome cohort. PLoS One 2021;16:e0258319. [PMID: 34748552 DOI: 10.1371/journal.pone.0258319] [Reference Citation Analysis]
210 Abbas F, El Kossi M, Kim JJ, Sharma A, Halawa A. Thrombotic microangiopathy after renal transplantation: Current insights in de novo and recurrent disease. World J Transplantation 2018; 8(5): 122-141 [PMID: 30211021 DOI: 10.5500/wjt.v8.i5.122] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 8] [Article Influence: 4.8] [Reference Citation Analysis]
211 De Vriese AS, Sethi S, Van Praet J, Nath KA, Fervenza FC. Kidney Disease Caused by Dysregulation of the Complement Alternative Pathway: An Etiologic Approach. J Am Soc Nephrol. 2015;26:2917-2929. [PMID: 26185203 DOI: 10.1681/asn.2015020184] [Cited by in Crossref: 53] [Cited by in F6Publishing: 27] [Article Influence: 7.6] [Reference Citation Analysis]
212 Keating GM. Eculizumab: a guide to its use in atypical haemolytic uraemic syndrome. Drugs Ther Perspect 2014;30:166-72. [DOI: 10.1007/s40267-014-0120-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
213 Amari Chinchilla K, Vijayan M, Taveras Garcia B, Jim B. Complement-Mediated Disorders in Pregnancy. Adv Chronic Kidney Dis 2020;27:155-64. [PMID: 32553248 DOI: 10.1053/j.ackd.2020.01.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
214 Ažukaitis K, Loirat C, Malina M, Adomaitienė I, Jankauskienė A. Macrovascular involvement in a child with atypical hemolytic uremic syndrome. Pediatr Nephrol 2014;29:1273-7. [PMID: 24352218 DOI: 10.1007/s00467-013-2713-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
215 Parisi M, Manni A, Caputo F, Trojano M, Paolicelli D. A case report of late-onset atypical Hemolytic Uremic Syndrome during interferon beta in multiple sclerosis: Open issues in literature review. Brain Behav 2021;11:e01930. [PMID: 33325640 DOI: 10.1002/brb3.1930] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
216 Schönermarck U, Ries W, Schröppel B, Pape L, Dunaj-Kazmierowska M, Burst V, Mitzner S, Basara N, Starck M, Schmidbauer D, Mellmann A, Dittmer R, Jeglitsch M, Haas CS. Relative incidence of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome in clinically suspected cases of thrombotic microangiopathy. Clin Kidney J 2020;13:208-16. [PMID: 32296526 DOI: 10.1093/ckj/sfz066] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
217 Godara A, Migliozzi DR, Pilichowska M, Goyal N, Varga C, Gordon CE. Use of Eculizumab in Transplant-Associated Thrombotic Microangiopathy in a Patient With Polycystic Kidney Disease Immediately Post-Kidney Transplant: A Case Report. Kidney Med 2020;2:652-6. [PMID: 33089142 DOI: 10.1016/j.xkme.2020.06.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
218 Kersnik Levart T, Ferluga D, Vizjak A, Mraz J, Kojc N. Severe active C3 glomerulonephritis triggered by immune complexes and inactivated after eculizumab therapy. Diagn Pathol. 2016;11:94. [PMID: 27717365 DOI: 10.1186/s13000-016-0547-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
219 Rousset-Rouvière C, Cailliez M, Garaix F, Bruno D, Laurent D, Tsimaratos M. Rituximab fails where eculizumab restores renal function in C3nef-related DDD. Pediatr Nephrol 2014;29:1107-11. [PMID: 24408225 DOI: 10.1007/s00467-013-2711-5] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 5.3] [Reference Citation Analysis]
220 Carcillo JA, Podd B, Aneja R, Weiss SL, Hall MW, Cornell TT, Shanley TP, Doughty LA, Nguyen TC. Pathophysiology of Pediatric Multiple Organ Dysfunction Syndrome. Pediatr Crit Care Med 2017;18:S32-45. [PMID: 28248832 DOI: 10.1097/PCC.0000000000001052] [Cited by in Crossref: 27] [Cited by in F6Publishing: 13] [Article Influence: 5.4] [Reference Citation Analysis]
221 Levi C, Frémeaux-bacchi V, Zuber J, Rabant M, Devriese M, Snanoudj R, Scemla A, Amrouche L, Mejean A, Legendre C, Sberro-soussan R. Midterm Outcomes of 12 Renal Transplant Recipients Treated With Eculizumab to Prevent Atypical Hemolytic Syndrome Recurrence. Transplantation 2017;101:2924-30. [DOI: 10.1097/tp.0000000000001909] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 3.4] [Reference Citation Analysis]
222 Roumenina LT, Rayes J, Frimat M, Fremeaux-Bacchi V. Endothelial cells: source, barrier, and target of defensive mediators. Immunol Rev 2016;274:307-29. [PMID: 27782324 DOI: 10.1111/imr.12479] [Cited by in Crossref: 54] [Cited by in F6Publishing: 56] [Article Influence: 10.8] [Reference Citation Analysis]
223 Jordan SC, Choi J, Vo A. Kidney transplantation in highly sensitized patients. Br Med Bull 2015;114:113-25. [PMID: 25935575 DOI: 10.1093/bmb/ldv013] [Cited by in Crossref: 46] [Cited by in F6Publishing: 30] [Article Influence: 6.6] [Reference Citation Analysis]
224 Bruel A, Kavanagh D, Noris M, Delmas Y, Wong EKS, Bresin E, Provôt F, Brocklebank V, Mele C, Remuzzi G, Loirat C, Frémeaux-Bacchi V, Fakhouri F. Hemolytic Uremic Syndrome in Pregnancy and Postpartum. Clin J Am Soc Nephrol 2017;12:1237-47. [PMID: 28596415 DOI: 10.2215/CJN.00280117] [Cited by in Crossref: 86] [Cited by in F6Publishing: 37] [Article Influence: 17.2] [Reference Citation Analysis]
225 Servais A, Devillard N, Frémeaux-Bacchi V, Hummel A, Salomon L, Contin-Bordes C, Gomer H, Legendre C, Delmas Y. Atypical haemolytic uraemic syndrome and pregnancy: outcome with ongoing eculizumab. Nephrol Dial Transplant 2016;31:2122-30. [PMID: 27587606 DOI: 10.1093/ndt/gfw314] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 7.7] [Reference Citation Analysis]
226 Pouw RB, Brouwer MC, de Gast M, van Beek AE, van den Heuvel LP, Schmidt CQ, van der Ende A, Sánchez-Corral P, Kuijpers TW, Wouters D. Potentiation of complement regulator factor H protects human endothelial cells from complement attack in aHUS sera. Blood Adv 2019;3:621-32. [PMID: 30804016 DOI: 10.1182/bloodadvances.2018025692] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
227 Singh K, Nadeem AJ, Doratotaj B. A rare case of thrombotic microangiopathy triggered by acute pancreatitis. BMJ Case Rep 2017;2017:bcr-2016-218581. [PMID: 28512098 DOI: 10.1136/bcr-2016-218581] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
228 Zimbudzi E. Overcoming technical challenges when treating atypical hemolytic uremic syndrome with therapeutic plasma exchange. Int J Nephrol Renovasc Dis 2013;6:245-8. [PMID: 24277990 DOI: 10.2147/IJNRD.S53074] [Reference Citation Analysis]
229 Thurman JM, Le Quintrec M. Targeting the complement cascade: novel treatments coming down the pike. Kidney Int. 2016;90:746-752. [PMID: 27325183 DOI: 10.1016/j.kint.2016.04.018] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
230 Ort M, Dingemanse J, van den Anker J, Kaufmann P. Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway. Front Immunol 2020;11:599417. [PMID: 33362783 DOI: 10.3389/fimmu.2020.599417] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
231 Salvadori M, Rosso G, Bertoni E. Complement involvement in kidney diseases: From physiopathology to therapeutical targeting. World J Nephrol 2015; 4(2): 169-184 [PMID: 25949931 DOI: 10.5527/wjn.v4.i2.169] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
232 Ardissino G, Testa S, Possenti I, Tel F, Paglialonga F, Salardi S, Tedeschi S, Belingheri M, Cugno M. Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases. Am J Kidney Dis. 2014;64:633-737. [PMID: 24656451 DOI: 10.1053/j.ajkd.2014.01.434] [Cited by in Crossref: 132] [Cited by in F6Publishing: 106] [Article Influence: 16.5] [Reference Citation Analysis]
233 Lemaire M, Noone D, Lapeyraque AL, Licht C, Frémeaux-Bacchi V. Inherited Kidney Complement Diseases. Clin J Am Soc Nephrol 2021;16:942-56. [PMID: 33536243 DOI: 10.2215/CJN.11830720] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
234 Noris M, Galbusera M, Gastoldi S, Macor P, Banterla F, Bresin E, Tripodo C, Bettoni S, Donadelli R, Valoti E, Tedesco F, Amore A, Coppo R, Ruggenenti P, Gotti E, Remuzzi G. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood. 2014;124:1715-1726. [PMID: 25037630 DOI: 10.1182/blood-2014-02-558296] [Cited by in Crossref: 189] [Cited by in F6Publishing: 171] [Article Influence: 23.6] [Reference Citation Analysis]
235 Palma LMP, Eick RG, Dantas GC, Tino MKDS, de Holanda MI; Brazilian Thrombotic Microangiopathy and Atypical Hemolytic Uremic Syndrome Study Group (aHUS Brazil). Atypical hemolytic uremic syndrome in Brazil: clinical presentation, genetic findings and outcomes of a case series in adults and children treated with eculizumab. Clin Kidney J 2021;14:1126-35. [PMID: 33841858 DOI: 10.1093/ckj/sfaa062] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
236 Hinson SR, Lennon VA, Pittock SJ. Autoimmune AQP4 channelopathies and neuromyelitis optica spectrum disorders. Handb Clin Neurol. 2016;133:377-403. [PMID: 27112688 DOI: 10.1016/b978-0-444-63432-0.00021-9] [Cited by in Crossref: 36] [Cited by in F6Publishing: 20] [Article Influence: 7.2] [Reference Citation Analysis]
237 Alpay N, Ozçelik U. Renal Transplantation in Patients With Atypical Hemolytic Uremic Syndrome: A Single Center Experience. Transplant Proc 2019;51:2295-7. [PMID: 31400975 DOI: 10.1016/j.transproceed.2019.01.157] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
238 Wehling C, Kirschfink M. Tailored eculizumab regimen for patients with atypical hemolytic uremic syndrome: requirement for comprehensive complement analysis. J Thromb Haemost 2014;12:1437-9. [DOI: 10.1111/jth.12639] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
239 Omura T, Watanabe E, Otsuka Y, Yoshida Y, Kato H, Nangaku M, Miyata T, Oda S. Complete remission of thrombotic microangiopathy after treatment with eculizumab in a patient with non-Shiga toxin-associated bacterial enteritis: A case report. Medicine (Baltimore) 2016;95:e4104. [PMID: 27399110 DOI: 10.1097/MD.0000000000004104] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
240 Asif A, Nayer A, Haas CS. Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab. J Nephrol 2017;30:347-62. [PMID: 27848226 DOI: 10.1007/s40620-016-0357-7] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 7.2] [Reference Citation Analysis]
241 Rasa M, Musgrave J, Abe K, Tanaka L, Xoinis K, Shiramizu B, Foskett G, Lau R. A Case of Escherichia coli Hemolytic Uremic Syndrome in a 10-Year-Old Male With Severe Neurologic Involvement Successfully Treated With Eculizumab. J Investig Med High Impact Case Rep 2017;5:2324709617741144. [PMID: 29152520 DOI: 10.1177/2324709617741144] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
242 Ito N, Ohashi R, Nagata M. C3 glomerulopathy and current dilemmas. Clin Exp Nephrol 2017;21:541-51. [PMID: 27878657 DOI: 10.1007/s10157-016-1358-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
243 Ito N, Hataya H, Saida K, Amano Y, Hidaka Y, Motoyoshi Y, Ohta T, Yoshida Y, Terano C, Iwasa T, Kubota W, Takada H, Hara T, Fujimura Y, Ito S. Efficacy and safety of eculizumab in childhood atypical hemolytic uremic syndrome in Japan. Clin Exp Nephrol 2016;20:265-72. [DOI: 10.1007/s10157-015-1142-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
244 Kalden JR. Emerging Therapies for Rheumatoid Arthritis. Rheumatol Ther 2016;3:31-42. [PMID: 27747522 DOI: 10.1007/s40744-016-0032-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
245 Schwartz J, Padmanabhan A, Aqui N, Balogun RA, Connelly-Smith L, Delaney M, Dunbar NM, Witt V, Wu Y, Shaz BH. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue. J Clin Apher. 2016;31:149-162. [PMID: 27322218 DOI: 10.1002/jca.21470] [Cited by in Crossref: 168] [Cited by in F6Publishing: 216] [Article Influence: 33.6] [Reference Citation Analysis]
246 Fakhouri F, Hourmant M, Campistol JM, Cataland SR, Espinosa M, Gaber AO, Menne J, Minetti EE, Provôt F, Rondeau E, Ruggenenti P, Weekers LE, Ogawa M, Bedrosian CL, Legendre CM. Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial. American Journal of Kidney Diseases 2016;68:84-93. [DOI: 10.1053/j.ajkd.2015.12.034] [Cited by in Crossref: 144] [Cited by in F6Publishing: 124] [Article Influence: 24.0] [Reference Citation Analysis]
247 Vester U, Mache CJ. Pharmacological treatment of atypical hemolytic-uremic syndrome. Expert Opinion on Orphan Drugs 2014;2:123-35. [DOI: 10.1517/21678707.2014.872029] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
248 Zhang L, Qiu W, Crooke S, Li Y, Abid A, Xu B, Finn MG, Lin F. Development of Autologous C5 Vaccine Nanoparticles to Reduce Intravascular Hemolysis in Vivo. ACS Chem Biol 2017;12:539-47. [PMID: 28045484 DOI: 10.1021/acschembio.6b00994] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
249 Mittal K, Cheema R, Mahajan V, Kumar P, Kaur R, Sood T, Kaur P. Challenges in management of atypical hemolytic uremic syndrome: Bottle neck in resource limited settings. Transfus Clin Biol 2021:S1246-7820(21)00091-4. [PMID: 34284115 DOI: 10.1016/j.tracli.2021.07.002] [Reference Citation Analysis]
250 Cassol CA, Brodsky SV, Satoskar AA, Blissett AR, Cataland S, Nadasdy T. Eculizumab deposits in vessel walls in thrombotic microangiopathy. Kidney International 2019;96:761-8. [DOI: 10.1016/j.kint.2019.05.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
251 Volk AL, Hu FJ, Berglund MM, Nordling E, Strömberg P, Uhlen M, Rockberg J. Stratification of responders towards eculizumab using a structural epitope mapping strategy. Sci Rep 2016;6:31365. [PMID: 27509843 DOI: 10.1038/srep31365] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
252 Barbour S, Gill JS. Advances in the understanding of complement mediated glomerular disease: implications for recurrence in the transplant setting. Am J Transplant. 2015;15:312-319. [PMID: 25612487 DOI: 10.1111/ajt.13042] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
253 Hou J, Markowitz GS, Bomback AS, Appel GB, Herlitz LC, Barry Stokes M, D'Agati VD. Toward a working definition of C3 glomerulopathy by immunofluorescence. Kidney Int 2014;85:450-6. [PMID: 24067430 DOI: 10.1038/ki.2013.340] [Cited by in Crossref: 107] [Cited by in F6Publishing: 91] [Article Influence: 11.9] [Reference Citation Analysis]
254 Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Frémeaux-Bacchi V, Kavanagh D, Nester CM, Noris M, Pickering MC, Rodríguez de Córdoba S, Roumenina LT, Sethi S, Smith RJ; Conference Participants. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney Int 2017;91:539-51. [PMID: 27989322 DOI: 10.1016/j.kint.2016.10.005] [Cited by in Crossref: 256] [Cited by in F6Publishing: 226] [Article Influence: 42.7] [Reference Citation Analysis]
255 Cataland SR, Wu HM. How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome. Blood 2014;123:2478-84. [PMID: 24599547 DOI: 10.1182/blood-2013-11-516237] [Cited by in Crossref: 86] [Cited by in F6Publishing: 61] [Article Influence: 10.8] [Reference Citation Analysis]
256 Bacchetta J, Mekahli D, Rivet C, Demède D, Leclerc AL. Pediatric combined liver-kidney transplantation: a 2015 update. Curr Opin Organ Transplant 2015;20:543-9. [PMID: 26270957 DOI: 10.1097/MOT.0000000000000225] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
257 Fakhouri F, Frémeaux-Bacchi V, Loirat C. Atypical hemolytic uremic syndrome: from the rediscovery of complement to targeted therapy. Eur J Intern Med 2013;24:492-5. [PMID: 23756030 DOI: 10.1016/j.ejim.2013.05.008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
258 Rigothier C, Delmas Y, Roumenina LT, Contin-bordes C, Lepreux S, Bridoux F, Goujon JM, Bachelet T, Touchard G, Frémeaux-bacchi V, Combe C. Distal Angiopathy and Atypical Hemolytic Uremic Syndrome: Clinical and Functional Properties of an Anti–Factor H IgAλ Antibody. American Journal of Kidney Diseases 2015;66:331-6. [DOI: 10.1053/j.ajkd.2015.03.039] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
259 Wong EK, Goodship TH, Kavanagh D. Complement therapy in atypical haemolytic uraemic syndrome (aHUS). Mol Immunol 2013;56:199-212. [PMID: 23810412 DOI: 10.1016/j.molimm.2013.05.224] [Cited by in Crossref: 60] [Cited by in F6Publishing: 54] [Article Influence: 6.7] [Reference Citation Analysis]
260 Muppidi S, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Nowak RJ, Andersen H, Casasnovas C, de Bleecker JL, Vu TH, Mantegazza R, O'Brien FL, Wang JJ, Fujita KP, Howard JF Jr; Regain Study Group. Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve 2019;60:14-24. [PMID: 30767274 DOI: 10.1002/mus.26447] [Cited by in Crossref: 30] [Cited by in F6Publishing: 37] [Article Influence: 10.0] [Reference Citation Analysis]
261 Kakita H, Miyake T, Komiya T, Tsukamoto T, Muso E. A case report of recurrent C3 glomerulonephritis 18 months after renal transplantation. Ren Replace Ther 2016;2. [DOI: 10.1186/s41100-016-0049-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
262 Zuber J, Le Quintrec M, Morris H, Frémeaux-Bacchi V, Loirat C, Legendre C. Targeted strategies in the prevention and management of atypical HUS recurrence after kidney transplantation. Transplant Rev (Orlando). 2013;27:117-125. [PMID: 23937869 DOI: 10.1016/j.trre.2013.07.003] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 6.2] [Reference Citation Analysis]
263 Joly BS, Zheng XL, Veyradier A. Understanding thrombotic microangiopathies in children. Intensive Care Med 2018;44:1536-8. [PMID: 29368057 DOI: 10.1007/s00134-018-5059-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
264 Ohta T, Urayama K, Tada Y, Furue T, Imai S, Matsubara K, Ono H, Sakano T, Jinno K, Yoshida Y, Miyata T, Fujimura Y. Eculizumab in the treatment of atypical hemolytic uremic syndrome in an infant leads to cessation of peritoneal dialysis and improvement of severe hypertension. Pediatr Nephrol 2015;30:603-8. [PMID: 25318620 DOI: 10.1007/s00467-014-2975-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
265 Bickel JK, Voisin TB, Tate EW, Bubeck D. How Structures of Complement Complexes Guide Therapeutic Design. Subcell Biochem 2021;96:273-95. [PMID: 33252733 DOI: 10.1007/978-3-030-58971-4_7] [Reference Citation Analysis]
266 Willows J, Brown M, Sheerin NS. The role of complement in kidney disease. Clin Med (Lond) 2020;20:156-60. [PMID: 32188650 DOI: 10.7861/clinmed.2019-0452] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
267 Lentine KL, Kasiske BL, Levey AS, Adams PL, Alberú J, Bakr MA, Gallon L, Garvey CA, Guleria S, Li PK, Segev DL, Taler SJ, Tanabe K, Wright L, Zeier MG, Cheung M, Garg AX. KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors. Transplantation 2017;101:S1-S109. [PMID: 28742762 DOI: 10.1097/TP.0000000000001769] [Cited by in Crossref: 72] [Cited by in F6Publishing: 79] [Article Influence: 14.4] [Reference Citation Analysis]
268 Mannucci P, Cugno M. The complex differential diagnosis between thrombotic thrombocytopenic purpura and the atypical hemolytic uremic syndrome: Laboratory weapons and their impact on treatment choice and monitoring. Thrombosis Research 2015;136:851-4. [DOI: 10.1016/j.thromres.2015.09.007] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
269 Sabry W, Elemary M, Burnouf T, Seghatchian J, Goubran H. Vitamin B12 deficiency and metabolism-mediated thrombotic microangiopathy (MM-TMA). Transfus Apher Sci 2020;59:102717. [PMID: 31902683 DOI: 10.1016/j.transci.2019.102717] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
270 Sharma S, Pradhan M, Meyers KE, Le Palma K, Laskin BL. Neonatal atypical hemolytic uremic syndrome from a factor H mutation treated with eculizumab. Clin Nephrol 2015;84:181-5. [PMID: 25816809 DOI: 10.5414/CN108532] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
271 Bergmann C. Advances in renal genetic diagnosis. Cell Tissue Res 2017;369:93-104. [PMID: 28597138 DOI: 10.1007/s00441-017-2636-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
272 Fakhouri F. Pregnancy-related thrombotic microangiopathies: Clues from complement biology. Transfus Apher Sci 2016;54:199-202. [PMID: 27158062 DOI: 10.1016/j.transci.2016.04.009] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 6.3] [Reference Citation Analysis]
273 Cataland SR, Wu HM. Diagnosis and management of complement mediated thrombotic microangiopathies. Blood Reviews 2014;28:67-74. [DOI: 10.1016/j.blre.2014.01.003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
274 Du Y, Zhang Q, Han B. Genetic variants of C5 and polymorphisms of C3 in Chinese patients with paroxysmal nocturnal hemoglobinuria. Int J Lab Hematol 2016;38:e84-5. [PMID: 27307199 DOI: 10.1111/ijlh.12512] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
275 Reuter S, Heitplatz B, Pavenstädt H, Suwelack B. Successful long-term treatment of TMA with eculizumab in a transplanted patient with atypical hemolytic uremic syndrome due to MCP mutation. Transplantation 2013;96:e74-6. [PMID: 24247905 DOI: 10.1097/01.TP.0000435705.63428.1f] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
276 Abbas F, El Kossi M, Jin JK, Sharma A, Halawa A. Recurrence of primary glomerulonephritis: Review of the current evidence. World J Transplant 2017; 7(6): 301-316 [PMID: 29312859 DOI: 10.5500/wjt.v7.i6.301] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
277 Kernan KF, Ghaloul-Gonzalez L, Shakoory B, Kellum JA, Angus DC, Carcillo JA. Adults with septic shock and extreme hyperferritinemia exhibit pathogenic immune variation. Genes Immun 2019;20:520-6. [PMID: 29977033 DOI: 10.1038/s41435-018-0030-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
278 Colla L, Diena D, Rossetti M, Manzione AM, Marozio L, Benedetto C, Biancone L. Immunosuppression in pregnant women with renal disease: review of the latest evidence in the biologics era. J Nephrol 2018;31:361-83. [DOI: 10.1007/s40620-018-0477-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
279 Chamberlain JL, Huda S, Whittam DH, Matiello M, Morgan BP, Jacob A. Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review. J Neurol 2021;268:1643-64. [PMID: 31482201 DOI: 10.1007/s00415-019-09498-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
280 Frangou E, Varnavidou-Nicolaidou A, Petousis P, Soloukides A, Theophanous E, Savva I, Michael N, Toumasi E, Georgiou D, Stylianou G, Mean R, Anastasiadou N, Athanasiou Y, Zavros M, Kyriacou K, Deltas C, Hadjianastassiou V. Clinical course and outcome after kidney transplantation in patients with C3 glomerulonephritis due to CFHR5 nephropathy. Nephrol Dial Transplant 2019;34:1780-8. [PMID: 30844074 DOI: 10.1093/ndt/gfz021] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
281 Ricklin D, Lambris JD. Complement in immune and inflammatory disorders: pathophysiological mechanisms. J Immunol 2013;190:3831-8. [PMID: 23564577 DOI: 10.4049/jimmunol.1203487] [Cited by in Crossref: 288] [Cited by in F6Publishing: 276] [Article Influence: 32.0] [Reference Citation Analysis]
282 Salvadori M, Bertoni E. Complement related kidney diseases: Recurrence after transplantation. World J Transplant 2016; 6(4): 632-645 [PMID: 28058212 DOI: 10.5500/wjt.v6.i4.632] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
283 Fukuzawa T, Nezu J. SKY59, A Novel Recycling Antibody for Complement-mediated Diseases. Curr Med Chem 2020;27:4157-64. [PMID: 31622197 DOI: 10.2174/0929867326666191016115853] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
284 Cao M, Ferreiro T, Leite BN, Pita F, Bolaños L, Valdés F, Alonso A, Vázquez E, Mosquera J, Trigás M, Rodríguez S. Two cases of atypical hemolytic uremic syndrome (aHUS) and eosinophilic granulomatosis with polyangiitis (EGPA): a possible relationship. CEN Case Rep 2017;6:91-7. [PMID: 28509134 DOI: 10.1007/s13730-017-0251-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
285 Schalk G, Kirschfink M, Wehling C, Gastoldi S, Bergmann C, Hoppe B, Weber LT. A complicated case of atypical hemolytic uremic syndrome with frequent relapses under eculizumab. Pediatr Nephrol 2015;30:1039-42. [PMID: 25752761 DOI: 10.1007/s00467-015-3078-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
286 Hohenstein B, Amann K, Menne J. Membranoproliferative Glomerulonephritis und C3‑Glomerulopathie. Internist 2019;60:458-67. [DOI: 10.1007/s00108-019-0572-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
287 Keir LS, Langman CB. Complement and the kidney in the setting of Shiga-toxin hemolytic uremic syndrome, organ transplantation, and C3 glomerulonephritis. Transfus Apher Sci 2016;54:203-11. [PMID: 27156109 DOI: 10.1016/j.transci.2016.04.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
288 Rodriguez-Osorio L, Ortiz A. Timing of eculizumab therapy for C3 glomerulonephritis. Clin Kidney J. 2015;8:449-452. [PMID: 26251715 DOI: 10.1093/ckj/sfv065] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
289 Kamel MH, Jaberi A, Gordon CE, Beck LH, Francis J. The Complement System in the Modern Era of Kidney Transplantation: Mechanisms of Injury and Targeted Therapies. Seminars in Nephrology 2022;42:14-28. [DOI: 10.1016/j.semnephrol.2022.01.006] [Reference Citation Analysis]
290 Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Muppidi S, Nowak RJ, O'Brien F, Wang JJ, Mantegazza R; REGAIN Study Group. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 2017;16:976-86. [PMID: 29066163 DOI: 10.1016/S1474-4422(17)30369-1] [Cited by in Crossref: 222] [Cited by in F6Publishing: 93] [Article Influence: 44.4] [Reference Citation Analysis]
291 Lee H, Kang E, Kang HG, Kim YH, Kim JS, Kim HJ, Moon KC, Ban TH, Oh SW, Jo SK, Cho H, Choi BS, Hong J, Cheong HI, Oh D. Consensus regarding diagnosis and management of atypical hemolytic uremic syndrome. Korean J Intern Med. 2020;35:25-40. [PMID: 31935318 DOI: 10.3904/kjim.2019.388] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
292 Touzot M, Obada EN, Beaudreuil S, François H, Durrbach A. Complement modulation in solid-organ transplantation. Transplant Rev (Orlando) 2014;28:119-25. [PMID: 24996770 DOI: 10.1016/j.trre.2014.03.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
293 Tseng MH, Tsai JD, Tsai IJ, Huang SM, Huang JL, Fan WL, Lee HJ, Wu TW, Lin SH. Whole-exome sequencing detects mutations in pediatric patients with atypical hemolytic uremic syndrome in Taiwan. Clin Chim Acta 2019;494:143-50. [PMID: 30905589 DOI: 10.1016/j.cca.2019.03.1623] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
294 Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaimé F, Dragon-Durey MA, Ngo S, Moulin B, Servais A, Provot F, Rostaing L. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol. 2013;8:554-562. [PMID: 23307876 DOI: 10.2215/cjn.04760512] [Cited by in Crossref: 385] [Cited by in F6Publishing: 194] [Article Influence: 42.8] [Reference Citation Analysis]
295 Sperati CJ, Moliterno AR. Thrombotic Microangiopathy. Hematology/Oncology Clinics of North America 2015;29:541-59. [DOI: 10.1016/j.hoc.2015.02.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
296 Michaux K, Bacchetta J, Javouhey E, Cochat P, Frémaux-Bacchi V, Sellier-Leclerc AL. Eculizumab in neonatal hemolytic uremic syndrome with homozygous factor H deficiency. Pediatr Nephrol 2014;29:2415-9. [PMID: 25149852 DOI: 10.1007/s00467-014-2933-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
297 Cavero T, Rabasco C, López A, Román E, Ávila A, Sevillano Á, Huerta A, Rojas-Rivera J, Fuentes C, Blasco M, Jarque A, García A, Mendizabal S, Gavela E, Macía M, Quintana LF, María Romera A, Borrego J, Arjona E, Espinosa M, Portolés J, Gracia-Iguacel C, González-Parra E, Aljama P, Morales E, Cao M, Rodríguez de Córdoba S, Praga M. Eculizumab in secondary atypical haemolytic uraemic syndrome. Nephrol Dial Transplant 2017;32:466-74. [PMID: 28339660 DOI: 10.1093/ndt/gfw453] [Cited by in Crossref: 67] [Cited by in F6Publishing: 59] [Article Influence: 13.4] [Reference Citation Analysis]
298 Naqvi R. Hemolytic Uremic syndrome associated with pregnancy: Outcome from acute Kidney Injury. Pak J Med Sci 2020;36:1153-7. [PMID: 32968372 DOI: 10.12669/pjms.36.6.2931] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
299 Chanchlani R, Thorner P, Radhakrishnan S, Hebert D, Langlois V, Arora S, Barth D, Cattran D, Kirschfink M, Licht C. Long-term Eculizumab Therapy in a Child With Refractory Immune Complex-Mediated Membranoproliferative Glomerulonephritis. Kidney Int Rep 2018;3:482-5. [PMID: 29725653 DOI: 10.1016/j.ekir.2017.08.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
300 Kourouklaris A, Ioannou K, Athanasiou I, Panagidou A, Demetriou K, Zavros M. Postpartum thrombotic microangiopathy revealed as atypical hemolytic uremic syndrome successfully treated with eculizumab: a case report. J Med Case Rep 2014;8:307. [PMID: 25219386 DOI: 10.1186/1752-1947-8-307] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
301 de Wit Y, Rethans A, van Mierlo G, Wouters D, ten Brinke A, Bemelman FJ, Zeerleder S. Plasma Exchange Therapy Using Solvent Detergent-Treated Plasma: An Observational Pilot Study on Complement, Neutrophil and Endothelial Cell Activation in a Case Series of Patients Suffering from Atypical Hemolytic Uremic Syndrome. Transfus Med Hemother. [DOI: 10.1159/000522137] [Reference Citation Analysis]
302 Java A, Edwards A, Rossi A, Pandey R, Gaut J, Delos Santos R, Miller B, Klein C, Brennan D. Cytomegalovirus-induced thrombotic microangiopathy after renal transplant successfully treated with eculizumab: case report and review of the literature. Transpl Int. 2015;28:1121-1125. [PMID: 25864519 DOI: 10.1111/tri.12582] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
303 Hassan S, Westwood J, Ellis D, Laing C, Mc Guckin S, Benjamin S, Scully M. The utility of ADAMTS13 in differentiating TTP from other acute thrombotic microangiopathies: results from the UK TTP Registry. Br J Haematol 2015;171:830-5. [DOI: 10.1111/bjh.13654] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 5.6] [Reference Citation Analysis]
304 Fukuzawa T, Sampei Z, Haraya K, Ruike Y, Shida-Kawazoe M, Shimizu Y, Gan SW, Irie M, Tsuboi Y, Tai H, Sakiyama T, Sakamoto A, Ishii S, Maeda A, Iwayanagi Y, Shibahara N, Shibuya M, Nakamura G, Nambu T, Hayasaka A, Mimoto F, Okura Y, Hori Y, Habu K, Wada M, Miura T, Tachibana T, Honda K, Tsunoda H, Kitazawa T, Kawabe Y, Igawa T, Hattori K, Nezu J. Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases. Sci Rep 2017;7:1080. [PMID: 28439081 DOI: 10.1038/s41598-017-01087-7] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 8.4] [Reference Citation Analysis]
305 Abe T, Sasaki A, Ueda T, Miyakawa Y, Ochiai H. Complement-mediated thrombotic microangiopathy secondary to sepsis-induced disseminated intravascular coagulation successfully treated with eculizumab: A case report. Medicine (Baltimore) 2017;96:e6056. [PMID: 28178155 DOI: 10.1097/MD.0000000000006056] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
306 Grisaru S. Management of hemolytic-uremic syndrome in children. Int J Nephrol Renovasc Dis 2014;7:231-9. [PMID: 24966691 DOI: 10.2147/IJNRD.S41837] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
307 Figuères ML, Frémeaux-Bacchi V, Rabant M, Galmiche L, Marinozzi MC, Grünfeld JP, Noël LH, Servais A. Heterogeneous histologic and clinical evolution in 3 cases of dense deposit disease with long-term follow-up. Hum Pathol 2014;45:2326-33. [PMID: 25260719 DOI: 10.1016/j.humpath.2014.07.021] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
308 Jensen RK, Pihl R, Gadeberg TAF, Jensen JK, Andersen KR, Thiel S, Laursen NS, Andersen GR. A potent complement factor C3-specific nanobody inhibiting multiple functions in the alternative pathway of human and murine complement. J Biol Chem 2018;293:6269-81. [PMID: 29497000 DOI: 10.1074/jbc.RA117.001179] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
309 Michels MAHM, van de Kar NCAJ, Okrój M, Blom AM, van Kraaij SAW, Volokhina EB, van den Heuvel LPWJ. Overactivity of Alternative Pathway Convertases in Patients With Complement-Mediated Renal Diseases. Front Immunol 2018;9:612. [PMID: 29670616 DOI: 10.3389/fimmu.2018.00612] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
310 Winthrop KL, Mariette X, Silva JT, Benamu E, Calabrese LH, Dumusc A, Smolen JS, Aguado JM, Fernández-Ruiz M. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). Clin Microbiol Infect 2018;24 Suppl 2:S21-40. [PMID: 29447987 DOI: 10.1016/j.cmi.2018.02.002] [Cited by in Crossref: 94] [Cited by in F6Publishing: 75] [Article Influence: 23.5] [Reference Citation Analysis]
311 Phillips EH, Westwood JP, Brocklebank V, Wong EK, Tellez JO, Marchbank KJ, McGuckin S, Gale DP, Connolly J, Goodship TH, Kavanagh D, Scully MA. The role of ADAMTS-13 activity and complement mutational analysis in differentiating acute thrombotic microangiopathies. J Thromb Haemost 2016;14:175-85. [PMID: 26559391 DOI: 10.1111/jth.13189] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]